

1 **RNAi-based screen for pigmentation in *Drosophila***  
2 ***melanogaster* reveals regulators of brain dopamine**  
3 **and sleep**

4

5 Samantha L Deal<sup>1,2,3</sup>, Danqing Bei<sup>2,4</sup>, Shelley B Gibson<sup>2,4</sup>, Harim Delgado-Seo<sup>2,5</sup>, Yoko Fujita<sup>2,4</sup>,  
6 Kyla Wilwayco<sup>2,4</sup>, Elaine S Seto<sup>6,7,8</sup>, Amita Sehgal<sup>9,10</sup>, Shinya Yamamoto<sup>1,2,4,5,11,\*</sup>

7

8 <sup>1</sup>Program in Developmental Biology, Baylor College of Medicine (BCM), Houston, TX 77030, USA

9 <sup>2</sup> Jan and Dan Duncan Neurological Research Institute (NRI), Texas Children's Hospital (TCH),  
10 Houston, TX 77030, USA

11 <sup>3</sup>Department of Neuroscience, University of Pennsylvania, Philadelphia, Pennsylvania, USA

12 <sup>4</sup>Department of Molecular and Human Genetics, BCM, Houston, TX 77030, USA

13 <sup>5</sup>Department of Neuroscience, BCM, Houston, TX 77030 USA

14 <sup>6</sup>Department of Neurology, TCH, Houston, TX 77030, USA

15 <sup>7</sup>Epilepsy Center, TCH, Houston, TX 77030, USA

16 <sup>8</sup>Department of Neurophysiology, TCH, Houston, TX 77030, USA

17 <sup>9</sup> Chronobiology and Sleep Institute, Perelman School of Medicine at the University of  
18 Pennsylvania, Philadelphia, PA, USA.

19 <sup>10</sup>Howard Hughes Medical Institute, University of Pennsylvania, Philadelphia, PA, USA

20 <sup>11</sup>Development, Disease Models & Therapeutics Graduate Program, BCM, Houston, TX 77030,  
21 USA

22

23 \* Corresponding Author: Shinya Yamamoto

24 Correspondence: [yamamoto@bcm.edu](mailto:yamamoto@bcm.edu)

## 25      **Summary**

26      The dopaminergic system has been extensively studied for its role in behavior and neurological  
27      diseases. Despite this, we still know little about how dopamine levels are regulated *in vivo*. To  
28      identify regulators of dopamine, we utilized *Drosophila melanogaster* cuticle pigmentation as a  
29      readout, where dopamine is used as a precursor to melanin. We started by measuring dopamine  
30      from known pigmentation mutants (e.g. *tan*, *ebony*, *black*) and then performed an RNAi-based  
31      screen to identify new regulators. We found 153 hits, which were enriched for developmental  
32      signaling pathways and mitochondria-associated proteins. From 35 prioritized candidates, 11 had  
33      an effect on head dopamine levels. Effects on brain dopamine were mild even when the rate-  
34      limiting synthesis enzyme *Tyrosine hydroxylase (TH)* was knocked down, suggesting changes in  
35      dopamine levels are tightly regulated in the nervous system. We pursued two of our hits that  
36      reduced brain dopamine levels, *clueless* and *mask*. Further examination suggests that *mask*  
37      regulates transcription of *TH* and affects dopamine-dependent sleep patterns. In summary, by  
38      studying genes that affect cuticle pigmentation, we were able to identify genes that affect  
39      dopamine metabolism as well as a novel regulator of behavior.

40

41      Keywords: *Drosophila melanogaster*, dopamine, pigmentation, RNAi, screen, *mask*, sleep

## 42 Introduction

43 Dopamine is a conserved neurotransmitter that functions in the nervous system to regulate  
44 a variety of behaviors, including learning & memory, locomotion, reward, and sleep. In humans,  
45 disruptions in dopamine have been associated with neurological and neuropsychiatric disorders,  
46 including addiction, depression, sleep disorders, and schizophrenia.<sup>1-3</sup> In addition, one of the  
47 hallmarks of Parkinson's disease is early degeneration of dopaminergic neurons, and Parkinson's  
48 patients are often given a dopamine precursor, L-dihydroxyphenylalanine (L-DOPA), as a method  
49 for treating symptoms.<sup>4,5</sup> Most genetic research on dopamine biology has focused on  
50 dopaminergic signaling and transport. However, changes in dopamine levels can have a great  
51 impact on behavioral outcomes.<sup>6-8</sup> Thus, identifying genes that affect dopamine levels is critical  
52 to understanding and potentially treating dopamine-associated disorders.

53 Dopamine synthesis is a conserved process, whereby the amino acid tyrosine is converted  
54 into L-DOPA via the rate-limiting enzyme, Tyrosine hydroxylase (TH).<sup>9</sup> Then, L-DOPA is  
55 converted into dopamine via the enzyme Dopa decarboxylase (Ddc).<sup>10</sup> In mammals, dopamine is  
56 degraded via oxidation or methylation using the enzymes Monoamine oxidase (MAO) and  
57 Catechol-O-methyltransferase (COMT).<sup>11</sup> In invertebrates, dopamine degradation goes through  
58 β-alanylation via the β-alanyl amine synthase (encoded by the *ebony* gene in *Drosophila*  
59 *melanogaster*) and acetylation via the acetyltransferase (encoded by the *speck* gene in  
60 *Drosophila*).<sup>12</sup> In addition, insects also convert dopamine into melanin to form proper cuticle  
61 pigment and structure.<sup>13-15</sup> For example, knockdown of *TH* (also known as *pale (ple)* in  
62 *Drosophila*) or *Ddc* leads to a paler cuticle, and reduction of *ebony* or *speck* leads to a darker  
63 cuticle.<sup>13-15</sup>

64 Historically, *Drosophila* has been used to study dopamine biology in multiple contexts. In  
65 particular, the fly has been instrumental in dissecting the role of dopamine in learning and

66 memory.<sup>16,17</sup> Moreover, an extensive genetic toolkit has made it a great model system for  
67 dissecting dopaminergic neural circuitry and signaling.<sup>18–20</sup> Lastly, *Drosophila* has been used to  
68 study dopamine-related neurological diseases. In particular, the fly was instrumental in identifying  
69 and investigating the cellular functions of Parkinson disease's genetic risk factors, *PINK1* and  
70 *PRKN* (i.e. *Pink1* and *parkin* in <sup>21</sup>*Drosophila*).<sup>21</sup>

71 As well as being a tool for dissecting neural circuitry, the fast generation time and low  
72 maintenance cost makes *Drosophila* a great system for large-scale screening. Previously, a RNAi  
73 screen (11,619 genes, ~89% of genome) was performed to identify genes that affect  
74 mechanosensory organs and cuticle formation in the *Drosophila* thorax.<sup>22</sup> In this screen, the  
75 researchers found 458 genes that affected cuticle color upon knockdown, but no further validation  
76 was performed.

77 Here, we utilize the fly cuticle to identify novel regulators of dopamine. We start by  
78 systematically examining classical pigmentation genes for their effect on dopamine in the head  
79 and brain. These experiments revealed that genes involved in dopamine synthesis cause the  
80 expected reduction in dopamine. On the other hand, genes involved in dopamine degradation  
81 either have no effect or unexpectedly show reduced dopamine. We go on to characterize 458  
82 genes identified from the RNAi screen by Mummery-Widmer et al. (2009). We tested 330 of them  
83 with independent RNAi lines and validated 153 genes (~46%) with consistent cuticle pigmentation  
84 defects. We go on to examine 35 prioritized gene hits for their effect on dopamine levels. From  
85 this analysis, we found two genes, *mask* and *clu*, that reduced brain dopamine levels upon  
86 knockdown in dopaminergic neurons. Lastly, we used molecular biology and sleep behavioral  
87 studies to show that *mask* appears to alter brain dopamine through regulation of *TH* transcription.

88 **Results**

89 *Drosophila* pigmentation genes affect dopamine in unexpected ways

90 To systematically test if changes in pigmentation genes affect dopamine as theorized in  
91 the field, we characterized loss-of-function alleles of genes involved in dopamine metabolism  
92 (Figure 1A) for pigmentation phenotypes and dopamine levels. Since the enzymes required for  
93 dopamine synthesis (TH and Ddc) are essential for survival,<sup>23,24</sup> we took advantage of established  
94 RNAi lines and UAS/GAL4 system.<sup>25-28</sup> It is known that reduction of *TH* or *Ddc* causes pale  
95 pigmentation and reduced dopamine.<sup>9,10,14</sup> We validated our method by knocking down *TH* in the  
96 middle thorax using *pnr-GAL4* along with a verified RNAi,<sup>29</sup> which causes a strong pale cuticle  
97 phenotype (Figures 1B and 1C). We measured dopamine using HPLC, and in our hands, this  
98 RNAi reduces head dopamine levels by ~60% (Figure 1E) and brain dopamine levels by ~32%  
99 (Figure 1E'). *Ddc* knockdown causes a weaker effect than *TH* RNAi in the cuticle (Figures 1B and  
100 1D) and the head (~35% dopamine reduction, Figure 1E) and has no significant effect on  
101 dopamine in the brain (Figure 1E'). This may be due to the strength of the RNAi and/or enzyme  
102 level requirements (since TH is the rate-limiting enzyme).

103 To test genes implicated in dopamine degradation and cuticle development (i.e.  
104 pigmentation and structural rigidity), we examined known mutant alleles. These alleles cause  
105 darker or paler cuticles (Figures 1F-1L and 1F'-1L') depending on their role in melanin  
106 metabolism. Unexpectedly, *black*, *speck*, *straw* and *yellow* mutants reduce head dopamine levels  
107 (measured using HPLC, Figure 1Q), while *ebony* and *tan* mutants had no significant effect (Figure  
108 1Q). Next, we checked the brain expression patterns of pigmentation enzymes. Based on our  
109 own expression analysis (Figures 1M-1P) and previously reported expression data,<sup>30,31</sup> most are  
110 expressed in the fly brain, but their expression does not appear to overlap with DANs. None of  
111 these pigmentation gene mutations had a significant effect on brain dopamine (Figure 1R).

112        Together this data shows that changes in dopamine synthesis cause a paler cuticle, which  
113    reflects a reduction in dopamine, but changes in dopamine metabolism enzymes downstream of  
114    dopamine synthesis have pigmentation phenotypes that do not correlate with brain dopamine  
115    level differences.

116    **RNAi-based cuticle pigmentation screen**

117        Mining a previously published genome-wide scale RNAi screen,<sup>22</sup> we identified 458 genes  
118    with pigmentation defects. To check if these phenotypes can be reproduced, we located 718  
119    additional UAS-RNAi lines corresponding to 330 genes. 426 lines came from the National Institute  
120    of Genetics in Mishima, Japan,<sup>32</sup> and 292 came from the Transgenic RNAi Project (TRiP) at  
121    Harvard Medical School.<sup>25</sup> 153 genes caused pigmentation defects in at least one additional RNAi  
122    line, which validates the results for 46.4% of the previous screen's RNAi lines (VDRC collection,  
123    Figure 2A).

124        Our RNAi-based secondary screen produced a spectrum of phenotypes (Figure 2B), but  
125    the phenotypes strengths (mild, moderate, or strong) were equally represented (mild = 38%,  
126    moderate = 33%, strong = 29%, Figure 2D). Pigmentation color changes were classified in three  
127    primary categories, pale, dark, or mix (a combination of pale and dark in a single thorax), which  
128    were not equally represented (Figure 2E). Dark cuticle phenotypes were the most common (56%),  
129    with pale and mixed cuticle phenotypes seen in 28% and 16% of genes, respectively.

130        We performed a protein-network analysis (Figure 2C) and found a group of proteins  
131    previously linked to cuticle pigmentation as well as clusters related to RNA processing, ubiquitin  
132    proteasome system, mitochondria-associated proteins, and signaling pathway genes, Hippo and  
133    EGF (epidermal growth factor) signaling in particular. GO enrichment analysis highlighted terms  
134    associated with cuticle pigmentation, protein stability, and several signaling pathways (Figure S1).  
135    We also observed that 85% of our genes were conserved between *Drosophila* and human, an

136 enrichment from the 68% of conserved genes in the original screen gene list (11, 619, Figures 2F  
137 and S2).

138 In summary, the cuticle pigmentation screen identified a spectrum of pale, dark and mixed  
139 phenotypes in 153 genes, showing a validation of ~50% from the original screen. Close  
140 examination of these hits highlights conserved molecular processes.

141 **Many pigmentation genes isolated have a neurological consequence**

142 To investigate if our gene candidates have a neurological consequence, we first checked  
143 if their homologs are associated with a neurological disease. Importantly, we defined homologs  
144 or conserved genes as genes where an ortholog prediction algorithm (DRSC Integrative Ortholog  
145 Prediction Tool) had a human gene with a score greater than or equal to three. We found that  
146 51.2% of the fly gene homologs are associated with a disease, 78% of those have at least one  
147 disease with neurological phenotypes (Table 1 and Figure S2), such as intellectual disability,  
148 autism spectrum disorder, ataxia, epilepsy, and cerebral atrophy.

149 Since dopamine is known to regulate locomotion and sleep,<sup>22,33</sup> we screened for  
150 locomotion and sleep defects using the Drosophila Activity Monitor (DAM).<sup>34</sup> We tested 274 RNAi  
151 lines from the NIG, TRiP, and VDRC RNAi collections corresponding to the validated 153 gene  
152 hits.<sup>35-37</sup> We scored the lines for total locomotion, total sleep, sleep bout length, and sleep latency  
153 during the night and day (Figure 3). There was a broad range in the RNAi lines for each of these  
154 phenotypes (Figure 3C). We classified RNAi lines as “outliers” if they were two standard  
155 deviations from the mean for a given phenotype (locomotion: 23 lines, total sleep: 20 lines, sleep  
156 bout length: 21 lines, sleep latency: 25 lines). While total sleep and locomotion strongly  
157 overlapped with each other, sleep latency and sleep bout length did not overlap with the other  
158 sleep phenotypes (Figure 3D). We assessed if certain gene categories (>10 genes) showed any  
159 distinct behavioral patterns (Figure 2C). There was no change in total locomotion or total sleep in

160 the categories assessed (Figures 3F and 3G). However, each category showed a distinct pattern  
161 in sleep bout length and latency (Figures 3F and 3H). This could indicate a distinction in how  
162 different gene functions could affect sleep. Since genes that affect sleep can often show distinct  
163 phenotypes (e.g. total sleep, bout number, latency, etc.) at distinct times of day,<sup>38</sup> any gene with  
164 one phenotype during the day or night was classified as an “outlier”. This produced 60 lines,  
165 corresponding to 50 genes.

166 Taken together, 77 of our 132 conserved genes are likely to have a neurological function,  
167 because they are implicated in human neurological disease (52 conserved genes) or were  
168 classified as a behavioral “outlier” (45 conserved genes).

## 169 11 genes alter dopamine levels in the fly head

170 To prioritize our gene list for dopamine measurement, we classified which of our genes  
171 were conserved in humans, as previously noted (132 conserved/153 pigmentation genes). Then,  
172 we prioritized these based on whether knockdown of these genes showed a strong pigmentation  
173 effect (38 genes), a behavioral effect in the DAM (45 genes), and/or a human neurological disease  
174 association (52 genes). 72% (95/132 conserved genes) were represented in one of these  
175 categories, and 29% (39/132) were represented in at least two (Figures 4A). We classified genes  
176 in two or more categories as priority hits and tested them for changes in dopamine using High  
177 Performance Liquid Chromatography (HPLC). We repeated previous results showing that  
178 knocking down *TH* or overexpressing a *TH* cDNA using *TH-GAL4* significantly reduces or  
179 increases head dopamine without effecting serotonin (Figures 4B and 4C).<sup>29</sup>

180 We found that 11 of 35 prioritized genes (note: some not tested due to lethality or stock  
181 issues) significantly altered head dopamine levels (Figures 4D and 4E). Since control NIG lines  
182 showed about ~80% dopamine levels compared to the TRiP collection (Figure S3), we compared  
183 the DA levels to control lines appropriate for each collection (e.g. UAS-lacZ RNAi). Unlike cuticle

184 pigmentation, where 65% of genes caused a dark cuticle (excludes mixed cuticle phenotype),  
185 most genes trended toward a reduction in dopamine (71%, 25/35, Figures 4F and 4G). There was  
186 no correlation between the cuticle color and the dopamine level in the fly head (Figure 4H).

187 In summary, our HPLC analysis on fly heads revealed 11 genes that significantly affect  
188 dopamine levels. We saw a trend in reduction in dopamine across all lines tested, and we  
189 observed no correlation between cuticle color and dopamine level.

190 **Brain studies reveal *mask* and *clueless* as regulators of brain dopamine**

191 To determine which of the 11 gene hits have consequences in the brain, we examined if  
192 their expression <sup>39-41</sup>overlapped with DANs. Looking at single-cell mRNA sequencing datasets,  
193 we saw that 10 of our genes overlapped with some DANs (Figure S5), though the expression  
194 overlap varied. *P/G-A* and *Sos* showed only ~3% overlap, and *Bsf* and *mask* showed 28% and  
195 35% overlap with <sup>42,43</sup>DANs, respectively.<sup>42,43</sup> For five of our genes, we were able to examine their  
196 expression using available T2A-GAL4 lines.<sup>39-41</sup> We found variability in the percentage of DANs  
197 with overlapping expression, but three of them (*Bsg*, *C/C-c*, and *P/G-A*) overlapped with ~75% of  
198 DANs, *rk* overlapped with ~45%, and *mask* overlapped with ~66% of the examined DAN clusters  
199 (Figures S5, S6, 5A, 5B-D, and 5B'-D'). For *clu*, we were able to examine expression using a  
200 protein trap line.<sup>44,45</sup> We saw that *clueless* protein appears to be enriched in DANs (Figures 5E,  
201 5F-5H and 5F'-5H').

202 The *TH-GAL4* line commonly used for dopamine studies misses a large portion of DANs,  
203 particularly in the PAM cluster (~87 DANs missed/~142 total DANs per hemisphere),<sup>46</sup> making it  
204 not ideal for quantifying total changes in brain dopamine. We recombined the *TH-GAL4* with  
205 another driver that hits a large portion of the PAM cluster neurons (*GMR58E02-GAL4* or *R58-*  
206 *GAL4*)<sup>18</sup> generating a recombined line (labelled *TH,R58-GAL4*) that hits ~95% of DANs (Figure  
207 S4). We microdissected adult fly brains and measured dopamine for our 11 gene hits. Most of

208 them showed no change in brain dopamine (Figure S5), but *mask* (*multiple ankyrin repeats single*  
209 *KH domain*) and *clueless* (*clueless*) knockdown reduced total brain dopamine for two independent  
210 RNAi lines (44,45Figures 5I).

211 In summary, our fly brain analysis revealed that at least six (*Bsg*, *C/C-c*, *clueless*, *mask*,  
212 *PIG-A*, *rk*) of our gene candidates show co-expression with TH, but only two genes (*clueless* and  
213 *mask*) significantly altered brain dopamine upon knockdown in the majority of DANs.

214 *mask* regulates Tyrosine Hydroxylase and alters sleep in a dopamine-  
215 dependent manner.

216 To test if *clu* and *mask* knockdown could be due to DAN loss, we quantified the number  
217 of DANs in several clusters.<sup>46</sup> There was no difference in neuron number for any cluster examined  
218 (Figures 5L and S6). Since our pigmentation gene study revealed that only the manipulation in  
219 TH reduced brain dopamine (Figure 1), we examined if knocking down our genes affect TH.  
220 Knockdown of *mask* led to a significant reduction in *TH* mRNA level for one RNAi (50% reduction),  
221 with the other RNAi trending (20-30% reduction, Figure 5J). Upon examining TH protein levels in  
222 DAN clusters, two clusters showed significant reduction in TH protein level, with other clusters  
223 showing a trend in TH protein reduction (PAL and PPM2/3, Figures 5K and S6). To assess  
224 behavioral consequences, we performed additional sleep analysis on *mask*. Dopamine is a wake-  
225 promoting agent, and complete loss of dopamine in the brain significantly increases sleep.<sup>47,48</sup>  
226 Knocking down *TH* using the *TH-GAL4* did not significantly alter total levels of sleep during light  
227 or dark periods (Figure S7), which may be due to the selective expression of the GAL4 or the  
228 partial reduction of dopamine (Figure 4C). However, two hours before light onset, there was a  
229 significant increase in sleep, accompanied by a reduction in the locomotor activity that anticipates  
230 light . Similarly, knockdown of *mask* with the *TH-GAL4* showed a highly consistent reduction in  
231 light anticipation (Figures 6A, 6B, 6B', and S8). When we feed the flies L-DOPA, the effect is no

232 longer seen (Figures 6C and S8). Additionally, in *Drosophila* caffeine's effects on sleep are  
233 mediated by dopamine through a point that is upstream of L-DOPA.<sup>49</sup> Based on this, we suspected  
234 that *mask* knockdown would ameliorate the effects of caffeine on sleep, since *mask* appears to  
235 reduce the synthesis of *TH*. We saw that caffeine's effect on total sleep and sleep in the dark is  
236 ameliorated upon *mask* knockdown (Figures 6D, 6E, and S8).

237 Follow up studies on *clueless* showed that *clueless* knockdown increases TH RNA level  
238 by about 1.5-2X, with no effect on TH protein level or TH+ neurons (Figure S9), and while there  
239 was an increase in sleep across several RNAi lines, there is no light anticipation phenotype.  
240 Feeding *TH>clu RNAi* flies L-DOPA was unable to rescue the *clueless* effects on sleep (Figure  
241 S9), suggesting that the effects on dopamine and TH may be a secondary effect. Additionally, the  
242 antioxidant NACA was also unable to rescue the sleep defects seen upon *clueless* knockdown  
243 (Figure S9).

244 In conclusion, *mask* appears to reduce total dopamine levels and sleep by affecting  
245 transcription of *TH*, while *clueless* is acting through an alternative mechanism.

## 246 Discussion

### 247 Validation of 148 novel cuticle pigmentation genes

248 Our RNAi screened confirmed 153 genes that were previously implicated in *Drosophila*  
249 pigmentation – 148 of these genes have not been previously associated with dopamine biology.  
250 Since we observed a strong enrichment for genes involved in pigmentation and tyrosine  
251 metabolism (Figure S1), our screening method effectively identified genes that are involved in the  
252 process of interest.

253        While prior research has compared genes that overlap with different types of screening  
254    strategies (e.g. chemical mutagenesis vs. RNAi), most RNAi phenotypes from large-scale screens  
255    have not been validated with alternative RNAi lines or collections. The original source RNAi  
256    screen used the lines available at the VDRC stock center.<sup>35,37</sup> Alternative sources for RNAi lines  
257    (i.e. TRiP and NIG) start with different backgrounds, vectors, hairpin lengths, insertion methods,  
258    and/or target different areas of the gene.<sup>36,50</sup> This allows researchers to overcome the off-targeting  
259    and weak silencing seen with RNAi analysis, but to our knowledge, there have been no screens  
260    or meta-analyses to test consistency from different lines. In this study, we found that ~46.4%  
261    (153/330) of genes with a pigmentation phenotype showed a phenotype in an alternative RNAi,  
262    and 87% of those phenotypes showed agreement in pigmentation color, highlighting that  
263    pigmentation as a phenotype is relatively consistent (Figure S10).

264        Interestingly, 85% of our genes had a homolog, whereas the original RNAi screen list  
265    (11,619 genes) had 68% of genes with a homology (1.25-fold enrichment, Figure S2). This is  
266    striking since dopamine cuticle pigmentation is an invertebrate-specific phenomenon,<sup>12</sup> and the  
267    enrichment suggests this phenotype is relevant for a conserved biological pathway. We propose  
268    that cuticle pigmentation may be a “phenolog”<sup>51</sup> of certain neurological traits in mammals.<sup>51</sup>

## 269    Protein-protein interaction network highlights unexpected gene associations

270        When we investigated what kind of gene categories were found in the pigmentation  
271    screen, we saw clusters that are associated with ubiquitin-proteasome system (UPS), RNA  
272    processing, mitochondria, and developmental signaling pathways. Each of these processes could  
273    be relevant to dopamine biology. For example, there is some evidence that the UPS system  
274    regulates TH levels in the mammals since inhibition of the UPS system has been shown to  
275    increase the TH protein in a PC12 rat cell line.<sup>52,53</sup> In addition, changes in RNA processing could  
276    indicate changes in the dopamine synthesis enzymes TH and Ddc since these enzymes undergo

277 RNA processing to create two different isoforms.<sup>54</sup> The TH isoforms differ in tissue expression  
278 and kinetics.<sup>55</sup> In mammals, post-transcriptional trafficking of TH mRNA and translational  
279 regulation has been suggested to be important for its function.<sup>56</sup>

280 We identified 12 genes that are known to function at the mitochondria, mostly in the  
281 electron transport chain (*ND-13B*, *ND-42*, *COX5A*), mitochondrial mRNA translation (*mRpL47*,  
282 *mRpL48*, *CG4679*), and mitochondrial protein localization (*CG8728*, *clu*, *mask*, *Mpcp2*). It is well-  
283 known that the mitochondria have a key role in dopamine metabolism in mammals since MAO  
284 acts in the mitochondria to degrade dopamine. However, there is no known MOA homolog in  
285 flies.<sup>12</sup> The metabolites for oxidation and methylation of dopamine (DOPAC and HVA) have been  
286 observed in flies though,<sup>57–60</sup> and we saw that dopamine degradation enzyme mutants (*ebony*,  
287 *tan*, and *speck*)<sup>61,62</sup> had no effect on dopamine in the brain (Figure 1). It is possible that there is  
288 an alternative process that regulates dopamine degradation in the brain, and the mitochondria  
289 may be involved.

290 The last major group of genes identified from our screen was developmental signaling,  
291 specifically EGF signaling and Hippo signaling. To date, neither EGF nor Hippo signaling have an  
292 established connection with dopamine biology in *Drosophila*. We may have pulled these genes  
293 out is because forming the dorso-central thorax is developmentally regulated.<sup>63–65</sup> However, we  
294 did not identify core components of the other key pathways, such as Notch or Hedgehog,  
295 suggesting that EGF and Hippo are more specifically involved in this pigmentation process.

296 **Cuticle pigmentation phenotypes may not reflect changes in dopamine**

297 The field has generally assumed that a darker cuticle reflects an elevated level of  
298 dopamine.<sup>15,66</sup> However, when we measured dopamine from degradation enzyme mutants using  
299 HPLC, we saw either no effect on dopamine level or reduced level of dopamine in the head. In  
300 addition, when we measured dopamine from the pigmentation genes from the screen, a darker

301 cuticle did not reflect elevated levels of dopamine in the head. While we were able to increase  
302 dopamine by 3-5 fold upon TH cDNA overexpression in the head (Figure 4C), this phenomenon  
303 was not observable in the brain. One reason could be that there is a selective pressure or a strong  
304 feedback mechanism that prevents elevated levels of dopamine in the nervous system. Since  
305 oxidized dopamine could be toxic,<sup>67</sup> this could be a mechanism to prevent cell toxicity.  
306 Regardless, changes in cuticle pigmentation do not necessarily reflect changes in dopamine level.

307 Upon seeing alterations of dopamine in the head for some of the classic pigmentation  
308 genes, we tested if this corresponded to changes in the brain. In the case of established dopamine  
309 synthesis genes, we saw a mild reduction in dopamine (~25%) upon knockdown of the rate-  
310 limiting enzyme, *TH*, and no effect upon knockdown of *Ddc*. In addition, we saw no effect on brain  
311 dopamine from dopamine degradation enzymes. Taken together, this suggests that brain  
312 dopamine is under very tight regulation, and effects on the enzymes may be difficult to see in total  
313 dopamine level. It also highlights how our approach will likely miss relevant candidates. In  
314 addition, upon looking at expression in the brain of dopamine degradation enzymes, we saw they  
315 did not overlap well with DANs. It may be that dopamine degradation does not happen in the  
316 neurons since it was hypothesized to occur in the glia.<sup>31,68</sup> However, the expression does not  
317 match a broad glial expression either. For the 11 genes from the pigmentation RNAi screen that  
318 showed altered levels of dopamine, only 2 (18%) of them showed an effect on dopamine in the  
319 brain. These results highlight how head dopamine levels should not be used as a proxy for brain  
320 dopamine levels.

321 ***clu* and *mask* reduce brain dopamine levels through different mechanisms**

322 Once we identified that knockdown of *clueless* and *mask* both reduced dopamine in the  
323 brain without affecting the number of DANs, we hypothesized that they may be acting through

324 TH. This is primarily because our initial dopamine metabolism studies showed that only changes  
325 in TH significantly affected dopamine levels in the brain.

326 *mask* encodes a scaffolding molecule that functions in multiple contexts.<sup>69–71</sup> In this study,  
327 *mask* knockdown reduced *TH* mRNA and protein levels, suggesting it acts on TH transcription.  
328 Follow-up behavior analysis showed that *mask* knockdown in DANs led to a highly consistent  
329 change in sleep. Specifically, *mask* knockdown reduced the number of flies that anticipated light.  
330 While fruit flies typically start to wake before light onset,<sup>72</sup> loss of *mask* in DANs suppresses this  
331 anticipation behavior. Importantly, dopamine has a role in sleep that goes beyond light  
332 anticipation, and complete loss of dopamine causes a global increase in sleep in the day and  
333 night.<sup>73</sup> The phenotype we observe is not this severe, which may be due to the GAL4 driver not  
334 hitting all DANs or the fact that this knockdown is only reducing dopamine by a modest 15–20%  
335 (Figure 5). This is supported by the similar phenotype with the *TH* RNAi and the DAN driver  
336 (*TH>TH* RNAi, Figure S7). There may be a circadian component as well. It is plausible that  
337 dopamine synthesis increases before wake at light onset, and manipulations that affect TH levels  
338 may struggle to keep up with the dopamine synthesis required at this time of day.

339 When we fed *mask* knockdown flies the precursor for dopamine, L-DOPA, this abolished  
340 the effect on light anticipation. We suspect that feeding L-DOPA does not override all sleep-  
341 dependent effects because clueless sleep phenotypes remained when we fed them L-DOPA  
342 (Figure S9). There is evidence that in the fruit fly caffeine affects sleep through TH. Specifically,  
343 Nall et al. showed that caffeine's effect on sleep is absent in TH mutant flies, even if L-DOPA is  
344 given.<sup>49</sup> Since *mask* knockdown affects TH mRNA levels, we tested if *mask* knockdown would  
345 suppress the effects of caffeine. We found that the reduction in total sleep and sleep during the  
346 dark period normally seen upon caffeine administration were absent upon *mask* knockdown. This  
347 further supports that *mask* alters TH levels.

348            While we do not have any direct evidence for how *mask* may be altering TH levels, *mask*  
349    has been implicated in multiple biological pathways that were highlighted from our screen,  
350    including EGF signaling (e.g. *Egfr*, *Sev*, *Raf*), Hippo signaling (e.g. *hpo*, *wts*, *mats*), and  
351    mitochondrial biology.<sup>74-77</sup> Egf and Hippo signaling have well-known transcriptional effects,<sup>78,79</sup>  
352    but whether they may regulate TH transcription directly or indirectly in this context need further  
353    investigation. It is also possible that *mask* is acting in several of these pathways at once, which  
354    causes it to have a strong additive effect that produces a significant change in dopamine in the  
355    whole brain, while knockdown of individual pathways may have more restricted roles (e.g. *Egfr*,  
356    *Sos*, *hpo*).

357            In addition to *mask*, we also saw that knockdown of *clueless* leads to significant reduction  
358    in dopamine. However, when we explored the behavioral consequence of *clueless* knockdown, it  
359    did not show the same effect on sleep as *mask* or *TH* knockdown. In addition, the sleep phenotype  
360    was not rescued by L-DOPA, and molecular biology showed that *clueless* knockdown leads to an  
361    increase in *TH* mRNA with no change in *TH* protein. Taken together, this indicates that the effect  
362    on dopamine from *clueless* knockdown may be a secondary consequence. *clueless* encodes a  
363    ribonucleoprotein thought to act at the outer mitochondrial membrane to promote proper formation  
364    of protein complexes including mitophagy proteins like Pink1 and Parkin.<sup>80,81</sup> It also interacts with  
365    the ribosome and translocase complex at the mitochondrial membrane suggesting it acts as a  
366    regulator for mitochondrial protein translation and import.<sup>80,82</sup> Knockdown of *clueless* showed no  
367    effect on *TH* protein level, but since this is a mitochondrial protein, it may be more likely that the  
368    effect on dopamine is through the previously proposed roles of mitochondria in regulating  
369    dopamine levels.

370            Importantly, our analysis has focused on changes in dopamine caused by changes in  
371    synthesis or degradation. However, dopamine levels can also be regulated by changes dopamine  
372    trafficking through regulators like the dopamine transporter (DAT) or the vesicular monoamine

373 transporter (VMAT).<sup>12</sup> For example, a null allele of the *DAT*, *fumin*, causes elevated levels of  
374 dopamine that lead to behavioral phenotypes, including hyperactivity and reduction in sleep.<sup>48</sup>  
375 However, these mutants do not have any cuticle pigmentation defects. While the role of VMAT in  
376 cuticle pigmentation have not been investigated, whether dopamine secretion from the epithelial  
377 cells remains a mystery. Therefore, it would be important to further study whether some of the  
378 hits from our screen may affect dopamine levels through altering dopamine transport via  
379 regulating DAT, VMAT or other mechanisms that regulates dopamine dynamics.

380 **Some regulators of dopamine levels may act locally**

381 When we examined the expression of some of our pigmentation genes in the brain (Figure  
382 S11), we found that many of them do not overlap with all DANs. This indicates that measuring  
383 global changes in dopamine may not be best for determining effects on DA for many of these  
384 genes. They may require targeted dopamine measurements, perhaps through a fixed or live  
385 reporter.<sup>83,84</sup> It is also possible to assess changes in dopamine using behavior, but this would  
386 require detailed assessment for each gene since behaviors are often cluster specific.<sup>85</sup>

387 In conclusion, our screen of identified novel pigmentation genes, a subset of which were  
388 identified as novel regulators of dopamine *in vivo*. Unbiased forward genetic screens in model  
389 organisms are powerful ways to identify unanticipated links between distinct biological pathways  
390 and provide new molecular handles to study the functional connections between them. Application  
391 of such strategies to the regulation of dopamine levels will likely continue to identify novel factors,  
392 some of which will impact our understanding of human neurological and neurodevelopmental  
393 diseases.

394 **Limitations of the study**

395 One key limitation to this study is that this screening approach will not capture all  
396 regulators of dopamine in the brain. The screen and most of the experiments are based off of  
397 RNAi lines. These lines were not verified for the initial and secondary screens. Some RNAis may  
398 not work. In addition, the RNAis often do not have the same effect as full mutants. For example,  
399 the TH RNAi, which has a known large effect on TH mRNA level (~90% reduction) still only  
400 reduces dopamine by ~30% in the brain. However, the full mutant for TH removes all dopamine  
401 from the brain. In addition to this the initial screen was based on pigmentation, and if a gene that  
402 regulates dopamine in the brain is not expressed in the cuticle, it would not have been captured.  
403 Our secondary screening uses total dopamine levels in the head and brain. It is likely that mild or  
404 cell-type specific changes in dopamine would not be captured through this approach. When we  
405 examined *clu* and *mask*, we focused on regulation through the dopamine synthesis enzymes.  
406 There are many ways that *clu* and *mask* could regulate dopamine, including through genes such  
407 as VMAT and DAT. We cannot rule out dopamine regulation through these alternative  
408 mechanisms.

## 409 **Resource Availability**

410 All data generated or analyzed during this study are included in this published article and its  
411 supplementary information files. This study did not generate any new unique reagents.

## 412 **Acknowledgements**

413 We thank the Bloomington *Drosophila* Stock Center (USA), the National Institutes Genetics Fly  
414 Stock Center (Japan), Vienna *Drosophila* RNAi Center (Austria) and Dr. Hugo Bellen for providing  
415 useful fly stocks and reagents for this project. We would like to thank Drs. Jonathan Andrews,  
416 Hugo Bellen, Brigitte Dauwalder, Herman Dierick, Lindsay Goodman, Oguz Kanca, Kartik  
417 Venkatachalam, Michael Wangler, Sheng Zhang, Huda Zoghbi, and the Sehgal lab for useful

418 suggestions, discussions and advice on the project. This work was supported by startup funds to  
419 Dr. Shinya Yamamoto from the Jan and Dan Duncan Neurological Research Institute at Texas  
420 Children's Hospital and the Department of Molecular and Human Genetics at Baylor College of  
421 Medicine, by the IRACDA program at the University of Pennsylvania (K12GM081259) for Dr.  
422 Samantha Deal, and by Howard Hughes Medical Institute (HHMI) for Dr. Amita Sehgal. Confocal  
423 microscopy at BCM was supported in part by the Intellectual and Developmental Disabilities  
424 Research Center (IDRRC, U54HD083092) from the Eunice Kennedy Shriver National Institute of  
425 Child Health & Human Development.

## 426 **Authors Contributions**

427 S.Y., E.S.S., A.S., and S.L.D. conceived the experiments. S.Y. and S.L.D. wrote the manuscript.  
428 S.Y., E.S.S., D.B., and S.L.D. conducted the pigmentation screen and DAM behavior analysis  
429 screen. S.L.D. and K.W. conducted the pigmentation mutant analysis experiments. S.L.D., S.B.G,  
430 H.D-S, Y.F., and K.W. conducted the HPLC analysis. S.L.D. and Y.F. performed confocal imaging.  
431 S.L.D. conducted all data analysis. All authors participated in the critical analysis of the  
432 manuscript.

## 433 **Declarations of Interests**

434 The authors declare no competing interests.

## 435 **Figure Titles and Legends**

436 **Figure 1. Manipulation of pigmentation enzymes have unexpected effects on dopamine.**  
437 (A) *Drosophila* dopamine metabolism pathway. Gene names encoding pigmentation enzymes are  
438 in blue and metabolites are in black. (B-D) Thorax phenotypes observed upon knockdown of

439 Tyrosine hydroxylase (TH, also known as Pale) (C) and Dopa decarboxylase (Ddc) (D) compared  
440 to control (B). (E-E') Dopamine levels, measured using HPLC, from the heads (E) and brains (E')  
441 upon knockdown of *TH* and *Ddc*. Pigmentation phenotypes observed mutant alleles in the thorax  
442 (F-L) and the body (F'-L') (Arrow in I' indicates the darker region characteristic of *speck* mutants).  
443 *T2A-GAL4* alleles for *black*, *speck*, and *tan* adult brain expression with dopaminergic neurons  
444 (DAN) staining in magenta (DANs) (M-P). (Q) Dopamine, measured using HPLC, in the heads of  
445 classical pigmentation mutants, *black*<sup>1</sup>, *ebony*<sup>1</sup>, *straw*<sup>1</sup>, and *yellow*<sup>1</sup>. (R) Dopamine levels in  
446 dissected brains of classical pigmentation mutants. Ordinary one-way ANOVA test with Dunnett  
447 multiple comparisons test. \*= $p<0.05$ , \*\*= $p<0.01$ , \*\*\*= $p<0.001$ , \*\*\*\*= $p<0.0001$ . Error bars show  
448 standard deviation (SD).

449 **Figure 2. RNAi pigmentation screen reveals a broad spectrum of phenotypes and classes**  
450 **of genes** (A) Flow chart depicting screening process. (B) Examples of the phenotypes observed  
451 from the RNAi-based pigmentation screen. (C) Protein-protein interaction network for 153 high  
452 confidence pigmentation gene hits from the RNAi-screen using STRING network analysis.  
453 Strength of line indicates confidence or strength of data support. Genes with no known  
454 interactions are not displayed. (D-F) Pie charts for the 153 pigmentation gene hits, including  
455 strength of phenotype (D), phenotype color (E), and conservation (F).

456 **Figure 3. *Drosophila* Activity Monitor (DAM) screen identifies behavior “outliers” and**  
457 **highlights distinct phenotypes for gene categories.** (A-B) Representative activity and sleep  
458 data measured in a neutral RNAi line (*mCherry RNAi*, A) and a behavioral “outlier” (*Raf RNAi*,  
459 B) knocked down in DANs (*TH-GAL4*). (C) Bar graph showing all RNAi lines tested for 24hr  
460 locomotion and total sleep during the 12hr light period, where light pink/blue represents fly lines  
461  $\pm 1SD$  away from the mean, and dark pink/blue are fly lines  $\pm 2SDs$  away from the mean (a.k.a.  
462 “outliers”). (D) Venn diagram of “outliers” for the four phenotypes examined (sleep latency, sleep  
463 bout length, locomotion, and total sleep). (E-H) Behavioral analysis of lines in three gene

464 categories captured in the pigmentation screen, including locomotion (E), sleep latency (F),  
465 sleep bout duration (G), and total sleep (H). Individual t-tests were performed to assess if genes  
466 in a category were significantly different to all other genes tested, and only those with a  $p < 0.10$   
467 are reported, with  $^* = p < 0.05$ .

468 **Figure 4. Eleven genes alter head dopamine upon knockdown.** (A) Venn diagram of the  
469 categories used to prioritize 39 genes (in yellow). (B) Representative chromatograms for  
470 dopamine (DA) and serotonin (5-HT) upon knockdown or overexpression of TH in Dopaminergic  
471 cells (*TH-GAL4*). (C) Quantification of DA and 5-HT from chromatograms. (D-E) HPLC analysis  
472 on prioritized genes for UAS-RNAi lines from NIG (D) and TRiP (E). (F-G) Pie charts for all  
473 genes for cuticle color (F) and trend in dopamine (G). (H) XY plot comparing pigmentation  
474 phenotype to dopamine levels. For (C) Brown-Forsythe ANOVA test performed with Dunnett's  
475 T3 multiple comparisons test. For (D) and (E) ordinary One-way ANOVA test with Dunnett's  
476 multiple comparisons test.  $^{**} = p < 0.01$ ,  $^{***} = p < 0.001$ ,  $^{****} = p < 0.0001$ . Error bars represent SD.

477 **Figure 5. Brain dopamine analysis identifies *mask* and *clu* as novel regulators of**  
478 **dopamine levels in the fly brain** (A) *mask<sup>T2A</sup>>mCh::nls* (represented as green) expression  
479 pattern in the adult brain colabelled with a TH antibody staining DANs (magenta), with specific  
480 clusters shown (B-D, B'-D'). (E) *clu::GFP* expression pattern in the adult brain colabelled with  
481 TH (magenta), with specific clusters shown (F-H, F'-H'). (I) Total dopamine in the adult fly brain  
482 upon knockdown of *mask* and *clu*. (J) qRT-PCR of TH upon *mask* knockdown with the  
483 recombined DAN (*TH, R58-GAL4*) driver. (K) Quantification of total TH protein level through  
484 immunofluorescence in DAN clusters upon knockdown of *mask*. (L) Quantification of TH positive  
485 (TH+) neurons in DAN clusters upon knockdown of *mask*. Ordinary one-way ANOVA was done  
486 with Dunnett's multiple comparisons test (I-L). Error bars represent SD. Scale bars are 50  $\mu\text{m}$  in  
487 (A) and (E) and 10  $\mu\text{m}$  in all others. Closed arrowheads represent some cells with coexpression

488 between *mask*<sup>T2A</sup>>*mCh::nls* and TH. Open arrowheads represent cells with TH staining and no  
489 *mask*<sup>T2A</sup>>*mCh::nls* expression.

490 **Figure 6. mask knockdown reduces TH mRNA and protein and causes sleep phenotypes**  
491 **that align with reduction in TH levels** (A) 24-hr sleep graph (sleep binned in 30-minute  
492 intervals) upon mask knockdown using the TH-GAL4. (B) Quantification of total sleep  
493 throughout the 12-hr dark period upon mask knockdown (B') Quantification of light anticipation  
494 upon mask knockdown. (C) Light anticipation in mask knockdown flies with L-DOPA feeding. (D-  
495 E) Caffeine effects on sleep upon mask knockdown – (D) Total Sleep and (E) Sleep during the  
496 12-hr dark period. For samples with more than one experimental, ordinary one-way ANOVAs  
497 were performed with Dunnett's multiple comparisons. (B, B', C). For samples with one  
498 experimental, individual t-tests were performed (D,E). \*= $p<0.05$ , \*\*= $p<0.01$ , \*\*\*\*= $p<0.0001$ . Error  
499 bars represent SD.

500 **Tables**

501 **Table 1. Fly pigmentation genes identified from this screen with neurological disease**  
502 **associated homologs in human.**

Fly Gene	Human Homologs with Neurological Phenotypes (DIOPT Score, Max=18)	Notable Neurological Phenotypes
AP-1sigma	AP1S2 (12), AP1S1 (11), AP2S1 (3)	ataxia, DD, seizures
ATP7	ATP7A (13), ATP7B (13)	dystonia, neurodegeneration, seizures, tremor
Atu	LEO1 (10)	ASD
byn	TBXT (11), TBX19 (10)	neural tube defects, seizures
CG16758	PNP (14)	ataxia, behavioral problems, spastic diplegia, tremor
CG4328	LMX1B (10)	spina bifida
CG43689	MYT1L (7)	DD, ID

CG4679	PTCD3 (14)	cerebral atrophy, myoclonus, psychomotor delay
CG5902	AAMERCR1 (13)	cerebral atrophy, early motor delay, myoclonus
CG8728	PMPCA (15)	ataxia
CIC-c	CLCN3 (12), CLCN4 (11), CLCNKA (3)	ID, language delay, seizures, structural abnormalities
ctrip	TRIP12 (10)	delayed speech, ID, psychomotor delay
Cyp301a1	CYP24A1 (5), CYP27B1 (4), CYP27A1 (4)	ataxia, motor delay, psychiatric symptoms, seizures
CysRS-m	CARS2 (15)	cerebral atrophy, epilepsy, psychomotor delay
Ddc	DDC (14), HDC (4)	dystonia, psychomotor delay, sleep disturbance
Dgp-1	GTPBP2 (3)	ataxia, dystonia, ID, psychomotor delay, seizures
Dscam2	DSCAM (10)	ASD
Egfr	ERBB4 (10), ERBB2 (10), ERBB3 (9)	ALS, axonal neuropathy, DD, seizures
Gbeta13F	GNB1 (15), GNB4 (13), GNB2 (12), GNB5 (3)	ADHD, CMT, DD, ID, language delay
gig	TSC2 (13)	brain structural abnormalities, seizures
Hrb98DE	HNRNPA2B1 (12), HNRNPA1 (9)	ALS, dementia, motor neuropathy
Itpr	ITPR1 (14), ITPR3 (11)	ataxia, cerebellar atrophy, motor delay
Khc	KIF5C (12), KIF5A (12)	ALS, psychomotor delay, seizures, spastic paraplegia
Larp7	LARP7 (10)	anxiety, DD, ID, unstable gait
LeuRS-m	LARS2 (15)	cognitive impairment, DD, dystonia, tremor, seizures
mask	ANKRD17 (10)	DD, ID, motor delay, speech delay
mbt	PAK1 (3), PAK3 (3), PAK2 (3)	ID, macrocephaly, seizures, speech delay
Membrin	GOSR2 (13)	cerebral atrophy, DD, seizures
Mp	COL18A1 (6)	ataxia, seizures

Mpcp2	SLC25A3 (14)	motor delay
ND-13B	NDUFA5 (13)	ASD
ND-42	NDUFA10 (14)	DD, structural abnormalities
Npc2b	NPC2 (7)	behavioral problems, DD, dementia, dystonia, seizures
per	PER3 (8), PER2 (7)	sleep abnormalities
PIG-A	PIGA (15)	seizures, structural abnormalities
ple	TH (15)	ataxia, dystonia, Parkinsonism, motor and sleep delay
Prosap	SHANK2 (10), SHANK3 (8)	ASD, DD, schizophrenia, seizures
Raf	BRAF (14), RAF1 (11)	DD, seizures
Rbp9	ELAVL2 (12), ELAVL3 (10)	ASD
rdx	SPOP (10)	DD, ID, speech delay
robo1	ROBO3 (8)	structural abnormalities
SCOT	OXCT1 (15)	coma, psychomotor delay
sesB	SLC25A4 (12)	motor delay, hyperreflexia
slp1	FOXG1 (6), FOXI1 (3), FOXJ1 (3), FOXC1 (3)	dystonia, motor delay, sleep and structural abnormalities
Smurf	ITCH (4), NEDD4L (3)	ID, psychomotor delay, seizures
Sod3	SOD1 (4)	ALS, spastic tetraplegia
Sos	SOS1 (14), SOS2 (12)	cognitive impair, learning disabilities
Spn38F	SERPINC1 (4), SERPINI1 (4)	cerebral atrophy, dementia, seizures
stv	BAG3 (9)	abnormal gait, behavioral problems, neuropathy
tws	PPP2R2A (13)	ataxia
Usp2	USP8 (4)	behavioral problems

Usp7	USP7 (13)	ID, psychomotor delay, seizures, structural abnormalities
------	-----------	---

503

504 **Table 1.** Homologs were defined as a Drosophila Integrative Orthology Prediction Tool (DIOPT,  
505 version 8.0) score greater than or equal to three. Neurological disease associations were based  
506 on Online Mendelian Inheritance in Man (OMIM)\_clincal disease phenotypes and high-confident  
507 ASD genes listed in Simons Foundation Autism Research Initiative (SFARI) gene database (class  
508 S, 1, 2 or 3). ASD=Autism Spectrum Disorder, DD=Developmental Delay, ID=Intellectual  
509 Disability, ALS=Amytrophic Lateral Sclerosis, CMT=Charcot-Marie-Tooth disease.

510 **STAR★Methods**

511 **Experimental Model and Study Participant Details**

512 Fly Maintenance and Stocks

513 Flies (*Drosophila melanogaster*) were reared at 25°C on a 12:12 Light/Dark (LD) and fed a  
514 molasses-based food source unless otherwise specific. Different temperatures were used to  
515 achieve different levels of gene knockdown or overexpression, which is documented for each  
516 experiment. Flies were transferred to a new vial 0-2 days post-eclosion (dpe) for age-appropriate  
517 analysis. Experiments were run on 3-7 dpe flies unless otherwise stated. Mutant and transgenic  
518 trains were obtained from Bloomington *Drosophila* Stock Center (BDSC,  
519 <https://bdsc.indiana.edu/>), Vienna Drosophila Research Center (VDRC,  
520 <https://www.viennabiocenter.org/vbcf/vienna-drosophila-resource-center/>), the Japanese  
521 National Institute of Genetics (<https://shigen.nig.ac.jp/fly/nigfly/>), or were gifts from scientists in  
522 the field or generated in house (S1 Table – S5 Table).

523 Fly Crosses

524 For the cuticle screen, *pnr-GAL4*<sup>86</sup> was crossed to the specified UAS-RNAi line (see S1 Table) at  
525 29°C, 25°C, and/or 18°C and examined after pigmentation is completed (>1 dpe). For the  
526 behavior and HPLC analysis *TH-GAL4* females (also called *p/le-GAL4*, BDSC stock #8848) were  
527 crossed to the specified RNAi line (see S2 Table). For all HPLC analysis, the controls were  
528 specific to the tested UAS-RNAi line.<sup>87</sup> Thus, the TRiP collection of RNAi lines are compared to  
529 the *UAS-mCherry(mCh)* RNAi line (BDSC #35785) and the NIG collection of RNAi lines as well  
530 as the VDRC RNAi lines are compared to the *UAS-lacZ* RNAi line. For the HPLC analysis  
531 performed on brains, we recombined the *TH-GAL4* with another DAN driver *GMR58E02-GAL4*  
532 (BDSC #41347), which expresses in a large group DANs in the PAM cluster.<sup>27</sup> These flies are  
533 referred to as *TH,R58-GAL4* throughout the article. The *TH,R58-GAL4* line was also used for  
534 qPCR and TH protein analysis via immunohistochemistry. For gene expression analysis *UAS-*  
535 *mCh::nls* (BDSC #38424) females were collected and crossed with respective T2A-GAL4 lines  
536 (see S5 Table). Female and males were both imaged at ~5-7dpe. For the follow-up sleep studies,  
537 the *UAS-RNAi* males were crossed with *TH-GAL4* virgins for the experimental. For the controls  
538 *w<sup>1118</sup>* females were crossed to males from either the *TH-GAL4* and *UAS-RNAi* lines  
539 independently.

540 **Method Details**

541 Notum Dissection and Imaging

542 For thorax analysis and dissection, males and females were both selected, though differences  
543 were not generally observed, and females are shown here. Flies that were 3-5 dpe were collected  
544 and placed in 70% EtOH. Notum dissection and imaging was previously published.<sup>88</sup> In summary,  
545 the thorax was dissected by removing the legs, abdomen, and head. Then the thorax was cut  
546 such that a hole was on the ventral side to allow solution to pass into the thorax. These dissected  
547 thoraces were placed in 10% KOH for 10 minutes at 90°C on a heat block. Then, the KOH was

548 removed and replaced with 70% EtOH solution. They were mounted on a slide prepared with tape  
549 on two sides in mounting media (50% glycerol, 50% EtOH). The thoraces were imaged on a  
550 stereo microscope (Leica MZ16) using OPTRONICS® MicroFIRE camera. The images are z-  
551 stack brightfield images taken and collapsed using extended depth of field in Image-Pro Plus 7.0  
552 and In-Focus (Version 1.6).

553 **Brain Expression Analysis**

554 Brain dissections and imaging were performed as previously reported.<sup>89</sup> In summary, the brains  
555 were dissected at 3-7 dpe in ice cold PBS and then fixed in 4% PFA in 0.5% PBST for 20 minutes.  
556 Then, they were washed with a quick wash in 0.5% PBST followed by three 10-20-minute washes  
557 in 0.5% PBST while on a rotator. The samples were placed in primary antibody solution [anti-  
558 Tyrosine Hydroxylase 1:500, PelFreez Biologicals, rabbit, P40101; anti-elav 1:100,  
559 Developmental Studies Hybridoma Bank, rat, 7E8A10 in solution (5% Normal Donkey Serum,  
560 0.1% NaN<sub>3</sub> in 0.5% PBST)] at 4°C for 3 days. Then, the samples were washed with a quick wash  
561 in 0.5% PBST followed by three 10-20-minute washes in 0.5% PBST while on a rotator. After the  
562 last wash, the samples were placed in a secondary antibody solution [anti-Rabbit 1:200 (Thermo  
563 Fisher Sci., Alexa-647, A-21208); anti-rat 1:200 (Thermo Fisher Sci., Alexa-488, A-27040) in  
564 solution (5% Normal Donkey Serum, 0.1% NaN<sub>3</sub> in 0.5% PBST)] for two hours at room  
565 temperature. The samples were washed again with one quick wash followed by three 10-20  
566 minutes washes in 0.5% PBST on a rotator. Then, the brains were mounted in Vectashield  
567 mounting media and imaged on a confocal microscope (Zeiss LSM 710 or Zeiss LSM 880). All  
568 images shown in this manuscript are Z-projection images that were generated using the ZEN  
569 software (Zeiss). Quantification of co-expression with DANs and the T2A-GAL4 lines was done  
570 by counting how many individual TH+ neurons for each cluster had a cell body labeled by the  
571 T2A-GAL4>*mCherry::nls* signal. This quantification was done per hemisphere. The single cell

572 sequencing expression analysis was done based on the DAN cluster from adult fruit fly data found  
573 in the Fly Cell Atlas, specifically using the data from Davie, Jannssens and Koldere et al., 2018.<sup>91</sup>

574 **RNAi-based Pigmentation Screen**

575 We identified pigmentation gene hits from a primary screen performed in Jurgen Knoblich's lab  
576 using the Vienna Drosophila Resource Center collection of RNAi lines by accessing their public  
577 RNAi screen database (<https://bristlescreen.imba.oeaw.ac.at/start.php>). The original screen was  
578 performed on 20,262 RNAi lines, encompassing 11,619 genes (~82% of protein-coding genes).<sup>22</sup>  
579 We selected genes that showed a cuticle pigmentation score for any RNAi line tested (gene  
580 scores ranged from two to ten). To validate pigmentation defects, we selected genes that had  
581 RNAi lines within the Fly National Institute of Genetics (NIG, 220 genes, 426 RNAi lines) or the  
582 Harvard Transgenic RNAi Project (TRiP, 221 genes, 292 RNAi lines) collections. Each RNAi line  
583 was tested at 29°C and 25°C. If there was no phenotype no further testing was performed. If it  
584 was lethal, we tested it at 18°C.

585 **Classification of Cuticle Phenotypes**

586 Phenotypes were scored using a qualitative scoring system. This system used *UAS-TH RNAi* and  
587 *UAS-ebony RNAi*, as a baseline for "strong". Then, lines were placed along the spectrum as mild,  
588 moderate, or strong. Phenotypes were scored by two independent observers and differences  
589 were settled by a third independent observer. If there was variability with one line or if there was  
590 variability amongst lines, this might appear as mild-moderate, moderate-strong, or mild-strong. In  
591 these cases, the strongest phenotype observed was documented as the recorded phenotype for  
592 a given gene.

593 **Protein-protein interaction network and gene ontology analysis**

594 The protein-protein interaction network was generated using STRING (search tool for recurring  
595 instances of neighboring genes, <https://string-db.org/>). For our data set we included these sources  
596 of interactions: gene neighborhoods (genes that are found close together across species),<sup>90</sup>  
597 curated databases (publicly available databases of protein interactions), and experimental  
598 evidence (known complexes and pathways from curated sources).<sup>92,93</sup> Any genes that did not  
599 interact with other genes from our screen were not included in the interaction network. This  
600 database was last accessed on 05/05/2023. The lines between genes represents the confidence  
601 in the interactions.

602 The gene ontology analysis was generated using GOrilla (Gene Ontology enRICHment anaLysis  
603 and visuaLizAtion tool, <https://cbl-gorilla.cs.technion.ac.il/>). The 153 pigmentation genes hits were  
604 included as target genes, and the background genes were the entire VDRC RNAi collection  
605 included in the Mummery-Widmer et al. 2009 screen. Only the GO terms with a p-value greater  
606 than 0.001 and a fold enrichment of greater than three were included in the analysis. Redundant  
607 terms were removed using Revigo (<http://revigo.irb.hr/>) with a stringency of 0.7. Those that have  
608 a fold enrichment greater than five were included in S1 Figure.

## 609 Human Neurological Disease Gene Classification

610 Homologs for each fly gene were identified using DIOPT (DRSC Integrative Ortholog Prediction  
611 Tool, v8.0, <https://www.flyrnai.org/diop>).<sup>94</sup> Genes were classified as orthologs if they had a  
612 DIOPT score $\geq 3$ . The human genes were scored as neurological disease-causing genes if they  
613 had an OMIM (Online Mendelian Inheritance of Man, last accessed 01/01/2023,  
614 <https://www.omim.org/>) disease association with any documented neurological phenotype.<sup>95</sup>  
615 Genes were also classified as human neurological disease genes if they were in the Simons  
616 Simplex Collection of Autism Spectrum Disorder gene list (last accessed 06/01/2022,  
617 <https://gene.sfari.org/>) and had a score equal to or less than 3 (1, 2, or 3) and/or syndromic (S).<sup>96</sup>

618 Behavior Analysis using the *Drosophila* Activity Monitor

619 *Behavior screen*

620 For the behavior screen, the crosses were set in a 12:12 LD chamber at 25°C and transferred  
621 every 2-3 days to increase the number of progenies. Upon eclosion, flies were transferred to 29°C  
622 and kept for 2-3 more days before testing. Individual tubes (PPT5x65 Polycarbonate, Trikinetics  
623 Inc, USA) appropriate for use with the *Drosophila* Activity Monitor (DAM, Model DAM2 for 5mm  
624 tubes, TriKinetics Inc, USA) were loaded with approximately ½" worth of molasses-based food.  
625 The end of the tube with food was sealed by placing the vial into Paraplast® (Sigma-Aldrich) wax  
626 three times and allowing it to dry. Once they were dry, individual male flies were placed into each  
627 vial, the vial was placed into the DAM recording chamber, and it was sealed using a 5mm tube  
628 cap (CAP5, TriKinetics Inc, USA) with a hole stuffed with cotton. For each genotype, 16 individual  
629 males were run, except in a few cases where we were unable to get that many flies. In which  
630 case, as many living males as possible were run. The flies were loaded into a 12:12 LD chamber  
631 at 29°C and monitored for 3 days. Then, the flies were removed and dead flies were eliminated  
632 from analysis.

633 Locomotion and sleep analysis was run on a 24-hour period, which started at the first onset of  
634 light after the flies were placed in the chamber (i.e. 18-24 hours after being placed in the chamber).  
635 Locomotion was calculated based on the number of beam crossings over the full 24 hours, the  
636 12 hours of light, and the 12 hours of dark. Sleep was classified as 5 minutes without any beam  
637 crossings. Total Sleep was quantified as total time spent sleeping over the 12 hours of light and  
638 the 12 hours of dark. Sleep latency was quantified as the amount of time after light onset or dark  
639 onset before a 5-minute period of sleep. Sleep Bout Length was quantified as the average length  
640 of sleep bouts (>5-minute period of sleep) during the 12 hours of light and 12 hours of dark.

641 “Outliers” were classified as lines that were more than two standard deviations from the mean of  
642 all lines for any of the phenotypes scored (24-hour locomotion, 12-hour light locomotion, 12-hour  
643 dark locomotion, 12-hour light total sleep, 12-hour dark total sleep, 12-hour light sleep bout length,  
644 12-hour dark sleep bout length, sleep latency during the light, or sleep latency during the dark).

645 ***Mask sleep study***

646 For these studies, similar tools and settings were used with these exceptions. Upon eclosion flies  
647 were transferred and kept at 25°C in group housing. For the behavior without drugs, individual  
648 males were placed in tubes with sucrose food (2% agar + 5% sucrose) at 3-6 dpe and behavioral  
649 analysis was collected and analyzed for the following five days. Sleep was then averaged across  
650 the five days for each individual fly before statistical analysis was performed. For the behavior  
651 with drugs, similar conditions were followed, except data was collected on the 2-6 days after they  
652 were loaded into behavior tubes to allow the drug to take effect. The following drug doses were  
653 used for their respective experiments (L-DOPA: 3mg/mL L-DOPA + 12.5 µg/mL carbidopa,  
654 caffeine: 0.5 mg/mL caffeine, NACA: 40 µg/mL N-acetylcysteine amide antioxidant). Drugs were  
655 dissolved directly into the sucrose food except for carbidopa which was dissolve in H<sub>2</sub>O at 1:50x  
656 concentration and then added into the sucrose food.

657 **High Performance Liquid Chromatography (HPLC) analysis**

658 ***HPLC System***

659 The HPLC used is an Antec® Scientific product with a LC110S pump, SYSTECH OEM MINI  
660 Vacuum Degasser, AS110 autosampler, a SenCell flow cell with salt bridge reference electrode  
661 in the Decade Lite. Data was collected and processed using DataApex Clarity™ chromatography  
662 software. The column used is chosen to work well for neurotransmitters (Acuity UPLC BEH C18

663 Column, 130Å, 1.7 µm, 1 mm X 100 mm with Acuity In-Line 0.2 µm Filter). The mobile phase  
664 was a 6% Acetonitrile mobile phase optimized for our samples (74.4 mg NA<sub>2</sub>EDTA·2H<sub>2</sub>O, 13.72  
665 mL 85% w/v phosphoric acid, 42.04 g citric acid, 1.2 g OSA, 120 mL acetonitrile, H<sub>2</sub>O up to 2L,  
666 pH=6.0 using 50% NaOH solution). The mobile phase was degassed for 10 minutes using the  
667 Bransonic® Ultrasonic Bath before being loaded into the HPLC machine.

668 The standards for HPLC were made by generating master stocks of 100 mM dopamine and 10  
669 mM serotonin diluted in MilliQ H<sub>2</sub>O, which were kept at 4°C. The day of HPLC analysis, the master  
670 stocks were diluted to produce standards ranging from 5-100 nM for 5-HT and 5-1000 nM for  
671 dopamine. Sample concentrations of dopamine (Sigma-Aldrich, Cat#H8502) and serotonin  
672 (Sigma-Aldrich, Cat#H7752) were calculated based on standards run in the same batch.  
673 Standards were compared to standards run on other days to assess for overall performance.

674 ***Sample Preparation***

675 For the HPLC on fly heads and brain, we adapted and modified the protocol previously  
676 published.<sup>97,98</sup> Crosses were reared at 29°C and flies were transferred into new tubes 0-2 days  
677 post eclosion (dpe). They remained at 29°C until they were 3-5 dpe. Female heads were collected  
678 by anesthetizing flies with CO<sub>2</sub> and cutting their heads off with a razor blade. Samples were  
679 collected between ZT04-ZT08. The heads were placed into 60 µL of 50 mM citrate acetate  
680 (pH=4.5) and either used for analysis that day or frozen at -20°C. Five heads were used per  
681 sample, and ~10 samples were run per genotype. The day of HPLC analysis, the samples were  
682 thawed and grounded using a pestle for 30 seconds (Cordless Pestle Motor and Fisherbrand™  
683 Disposable Pellet Pestle for 1.5mL tube). Then the samples were spun down at 13,000 rpm for  
684 10 minutes. The supernatant was removed and placed into a new vial. 10 µL from each sample  
685 was used for the Bradford Protein Analysis Assay. The rest of the sample solution (~40-50 µL)

686 was loaded into a vial (300  $\mu$ L Polypropylene Sample Vials with 8mm Snap Caps) for HPLC  
687 analysis.

688 For HPLC analysis on fly brains, flies were collected 3-7 dpe. Then, 10 fly brains (5 male, 5  
689 female) were dissected in ice cold PBS. Right after dissection, the brains were transferred to 60 $\mu$ L  
690 of ice cold 50mM citrate acetate (pH=4.5). Samples were frozen at -20°C and ran within 4 weeks  
691 of collection. The day of HPLC analysis, the samples were homogenized similarly to the fly heads,  
692 though for the Protein Assay, 20  $\mu$ L of sample was used. Then, the remaining solution was loaded  
693 for HPLC analysis.

694 ***Bradford Protein Analysis Assay***

695 The Bio-Rad Bradford Assay was used for colorimetric scoring of total protein. See product details  
696 for full description (Bio-Rad Protein Assay Kit I #5000001). Briefly, the dye reagent was diluted  
697 1:4 in MilliQ H<sub>2</sub>O. Then, the solution was filtered through a 0.22  $\mu$ m SFCA Nalgene filter. 10  $\mu$ L  
698 of each protein sample (standard or fly sample) was placed into single wells of a 96-well plate.  
699 Then, 200  $\mu$ L of diluted 1:4 dye reagent was added to each well. The samples rested for 30-45  
700 minutes and then absorbance was measured using BMG Labtech FLUOstar OPTIMA microplate  
701 reader. Protein measurements for each sample were calculated based on standards ran on the  
702 same plate.

703 **RNA expression analysis**

704 Flies were raised at 29°C until 5-7 dpe, then heads were collected by cutting them off with a razor.  
705 Twenty heads were collected per sample with a mixture of males and females and placed directly  
706 on dry ice. Samples were kept on dry ice or at -80°C until RNA isolation. For RNA isolation  
707 samples were homogenized in 200 $\mu$ L of TRIzol®. Then 800 $\mu$ L of TRIzol® was added and the  
708 samples were mixed by pipetting. The samples incubated for 5 minutes at room temperature and

709 were then spun down at 12,000 rpm for 10 minutes at 4°C. The supernatant was removed and  
710 200µL of chloroform was added. The samples were mixed by shaking and then incubated at room  
711 temperature for 3 minutes. Then, they were spun at 10,000 rpm for 15 minutes at 4°C, and the  
712 aqueous layer was collected and placed in a new tube. 500µL of isopropanol was added and the  
713 samples were left to incubate for 10 minutes at room temperature. The samples were spun at  
714 10,000 rpm for 10 minutes at 4°C and the supernatant was removed. The pellet was washed with  
715 1mL of 75% EtOH and centrifuged at 5,000 rpm for 5 minutes. All EtOH was removed and the  
716 pellet dried at room temperature for 10 minutes. Then, the pellet was dissolved in 100µL of H<sub>2</sub>O.  
717 RNA content and quality was measured using DeNovix DS-11 Fx spectrophotometer/fluorometer.  
718 cDNA reverse transcription was performed according to the iScript™ reverse transcriptase Bio-  
719 Rad kit and 2 µL of RNA sample was added in a 10 µL reaction for both the reverse and no  
720 reverse transcriptase reaction. Samples were measured for content and quality and then they  
721 were diluted to 100ng/µL. qPCR was performed using Bio-Rad iQ SYBR Green Supermix and  
722 measured on Bio-Rad CFX96™ Real-Time System. The TH primers used Forward: 5'-  
723 ATGTCGCCATCAAGAAATCCT-3' and Reverse: 5'-GGGTCTCGAACGGGCATC-3', and the  
724 control primers were for Rpl32 were Forward: 5'-ATGCTAAGCTGTCGCACAAATG-3' and  
725 Reverse: 5'-GTTCGATCCGTAACCGATGT-3'. For each sample, two technical replicates were  
726 run for the reverse transcriptase reaction, and the final quantity was based on the average of the  
727 two. If the no reverse transcriptase reaction produced a product that was a Cq within ten, the  
728 sample was discarded.

729 DAN and TH Quantification

730 Samples were stained and imaged like the brain expression analysis, except the primarily  
731 antibody solution included an Elav antibody [anti-Tyrosine Hydroxylase 1:500, PelFreez  
732 Biologicals, rabbit, P40101; anti-Elav 1:100, Developmental Studies Hybridoma Bank, rat,

733 7E8A10 in solution (5% Normal Donkey Serum, 0.1% NaN<sub>3</sub> in 0.5% PBST)]. Confocal imaging  
734 was performed as described above. Once the samples were imaged, anterior, posterior, and  
735 whole brain projections were generated that included all fluorescent signals from the anterior (PAL  
736 and PAM clusters) and posterior (PPL1, PPM2, PPM3, PPL2ab) neuron clusters of interest. The  
737 number of neurons per cluster (excluding the PAM cluster) were counted for each sample. PPM2  
738 and PPM3 clusters were counted together. For TH protein quantification samples were assessed  
739 using ImageJ. A boundary was drawn around each individual cluster and quantified. Then, the  
740 local background for that cluster was subtracted from the cluster to give the fluorescence for the  
741 given sample. Each hemisphere was treated as a separate sample.

## 742 Quantification and Statistical Analysis

743 Statistical analysis was performed using Graphpad Prism 10. Unless otherwise stated, all data  
744 was subjected to a ROUT outlier test, where all outliers were removed, and then a one-way  
745 ANOVA was performed. Each of the experimental samples were compared to the control for the  
746 given samples. In the cases where there were only two samples (i.e. control and experimental),  
747 a t-test was performed.

748 For the HPLC screen on heads, the samples were normalized to the controls run on that day. The  
749 TRiP collection was normalized to *UAS-mCh RNAi* control and the NIG collection was normalized  
750 to the *UAS-lacZ RNAi* control.

## 751 Supplemental Information

752 Document S1. Figures S1-S11

753 **Table S1. Screen results by RNAi line: Pigmentation, Drosophila Activity Monitor, HPLC,  
754 and Prioritization, related to Figures 2 - 4.**

755 **Table S2. Experimental models: Organisms/strains, related to Key resources table**

756

757 **References**

758 1. Radwan, B., Liu, H., and Chaudhury, D. (2019). The role of dopamine in mood disorders  
759 and the associated changes in circadian rhythms and sleep-wake cycle. *Brain Res* 1713,  
760 42–51. <https://doi.org/10.1016/J.BRAINRES.2018.11.031>.

761 2. Grace, A.A. (2016). Dysregulation of the dopamine system in the pathophysiology of  
762 schizophrenia and depression. *Nat Rev Neurosci* 17, 524–532.  
763 <https://doi.org/10.1038/NRN.2016.57>.

764 3. Nutt, D.J., Lingford-Hughes, A., Erritzoe, D., and Stokes, P.R.A. (2015). The dopamine  
765 theory of addiction: 40 years of highs and lows. *Nat Rev Neurosci* 16, 305–312.  
766 <https://doi.org/10.1038/NRN3939>.

767 4. Church, F.C. (2021). Treatment Options for Motor and Non-Motor Symptoms of  
768 Parkinson's Disease. *Biomolecules* 11. <https://doi.org/10.3390/BIOM11040612>.

769 5. Armstrong, M.J., and Okun, M.S. (2020). Diagnosis and Treatment of Parkinson Disease:  
770 A Review. *JAMA* 323, 548–560. <https://doi.org/10.1001/JAMA.2019.22360>.

771 6. López-Cruz, L., Miguel, N.S., Carratalá-Ros, C., Monferrer, L., Salamone, J.D., and  
772 Correa, M. (2018). Dopamine depletion shifts behavior from activity based reinforcers to  
773 more sedentary ones and adenosine receptor antagonism reverses that shift: Relation to  
774 ventral striatum DARPP32 phosphorylation patterns. *Neuropharmacology* 138, 349–359.  
775 <https://doi.org/10.1016/J.NEUROPHARM.2018.01.034>.

776 7. Steiner, H., and Kitai, S.T. (2001). Unilateral striatal dopamine depletion: time-dependent  
777 effects on cortical function and behavioural correlates. *Eur J Neurosci* 14, 1390–1404.  
778 <https://doi.org/10.1046/J.0953-816X.2001.01756.X>.

779 8. Rohwedder, A., Wenz, N.L., Stehle, B., Huser, A., Yamagata, N., Zlatic, M., Truman,  
780 J.W., Tanimoto, H., Saumweber, T., Gerber, B., et al. (2016). Four Individually Identified

781 Paired Dopamine Neurons Signal Reward in Larval *Drosophila*. *Curr Biol* 26, 661–669.

782 <https://doi.org/10.1016/J.CUB.2016.01.012>.

783 9. Budnik, V., and White, K. (1987). Genetic dissection of dopamine and serotonin synthesis

784 in the nervous system of *Drosophila melanogaster*. *J Neurogenet* 4, 309–314.

785 <https://doi.org/10.3109/01677068709167191>.

786 10. Livingstone, M.S., and Tempel, B.L. (1983). Genetic dissection of monoamine

787 neurotransmitter synthesis in *Drosophila*. *Nature* 303, 67–70.

788 <https://doi.org/10.1038/303067A0>.

789 11. Meiser, J., Weindl, D., and Hiller, K. (2013). Complexity of dopamine metabolism. *Cell*

790 *Commun Signal* 11. <https://doi.org/10.1186/1478-811X-11-34>.

791 12. Yamamoto, S., and Seto, E.S. (2014). Dopamine dynamics and signaling in *Drosophila*:

792 an overview of genes, drugs and behavioral paradigms. *Exp Anim* 63, 107–119.

793 <https://doi.org/10.1538/EXPANIM.63.107>.

794 13. Wittkopp, P.J., True, J.R., and Carroll, S.B. (2002). Reciprocal functions of the *Drosophila*

795 yellow and ebony proteins in the development and evolution of pigment patterns.

796 *Development* 129, 1849–1858. <https://doi.org/10.1242/DEV.129.8.1849>.

797 14. True, J.R., Edwards, K.A., Yamamoto, D., and Carroll, S.B. (1999). *Drosophila* wing

798 melanin patterns form by vein-dependent elaboration of enzymatic prepatterns. *Curr Biol*

799 9, 1382–1391. [https://doi.org/10.1016/S0960-9822\(00\)80083-4](https://doi.org/10.1016/S0960-9822(00)80083-4).

800 15. Spana, E.P., Abrams, A.B., Ellis, K.T., Klein, J.C., Ruderman, B.T., Shi, A.H., Zhu, D.,

801 Stewart, A., and May, S. (2020). speck, First Identified in *Drosophila melanogaster* in

802 1910, Is Encoded by the Arylalkalamine N-Acetyltransferase (AANAT1) Gene. *G3*

803 (Bethesda) 10, 3387–3398. <https://doi.org/10.1534/G3.120.401470>.

804 16. Gervasi, N., Tchénio, P., and Preat, T. (2010). PKA dynamics in a *Drosophila* learning

805 center: coincidence detection by rutabaga adenylyl cyclase and spatial regulation by

806 duncne phosphodiesterase. *Neuron* 65, 516–529.

807 <https://doi.org/10.1016/J.NEURON.2010.01.014>.

808 17. Heisenberg, M., Borst, A., Wagner, S., and Byers, D. (1985). Drosophila mushroom body

809 mutants are deficient in olfactory learning. *J Neurogenet* 2, 1–30.

810 <https://doi.org/10.3109/01677068509100140>.

811 18. Jenett, A., Rubin, G.M., Ngo, T.T.B., Shepherd, D., Murphy, C., Dionne, H., Pfeiffer, B.D.,

812 Cavallaro, A., Hall, D., Jeter, J., et al. (2012). A GAL4-driver line resource for Drosophila

813 neurobiology. *Cell Rep* 2, 991–1001. <https://doi.org/10.1016/J.CELREP.2012.09.011>.

814 19. Frighetto, G., Zordan, M.A., Castiello, U., Megighian, A., and Martin, J.R. (2022).

815 Dopamine Modulation of Drosophila Ellipsoid Body Neurons, a Nod to the Mammalian

816 Basal Ganglia. *Front Physiol* 13. <https://doi.org/10.3389/FPHYS.2022.849142>.

817 20. Xie, T., Ho, M.C.W., Liu, Q., Horiuchi, W., Lin, C.C., Task, D., Luan, H., White, B.H.,

818 Potter, C.J., and Wu, M.N. (2018). A Genetic Toolkit for Dissecting Dopamine Circuit

819 Function in Drosophila. *Cell Rep* 23, 652–665.

820 <https://doi.org/10.1016/j.celrep.2018.03.068>.

821 21. Clark, I.E., Dodson, M.W., Jiang, C., Cao, J.H., Huh, J.R., Seol, J.H., Yoo, S.J., Hay,

822 B.A., and Guo, M. (2006). Drosophila pink1 is required for mitochondrial function and

823 interacts genetically with parkin. *Nature* 441, 1162–1166.

824 <https://doi.org/10.1038/NATURE04779>.

825 22. Mummery-Widmer, J.L., Yamazaki, M., Stoeger, T., Novatchkova, M., Bhalerao, S.,

826 Chen, D., Dietzl, G., Dickson, B.J., and Knoblich, J.A. (2009). Genome-wide analysis of

827 Notch signalling in Drosophila by transgenic RNAi. *Nature* 458, 987–992.

828 <https://doi.org/10.1038/NATURE07936>.

829 23. Pendleton, R.G., Rasheed, A., Sardina, T., Tully, T., and Hillman, R. (2002). Effects of

830 Tyrosine Hydroxylase Mutants on Locomotor Activity in Drosophila: A Study in Functional

831 Genomics.

832 24. Wright, T.R.F., Bewley, G.C., and Sherald3, A.F. (1976). THE GENETICS OF DOPA  
833 DECARBOXYLASE IN DROSOPHILA MELANOGASTER. 11. ISOLATION AND  
834 CHARACTERIZATION OF DOPA-DECARBOXY LASE-DEFICIENT MUTANTS AND  
835 THEIR RELATIONSHIP TO THE  $\alpha$ -METHYL-DOPA-HYPERSENSITIVE MUTANTS.

836 25. Ni, J.Q., Liu, L.P., Binari, R., Hardy, R., Shim, H.S., Cavallaro, A., Booker, M., Pfeiffer,  
837 B.D., Markstein, M., Wang, H., et al. (2009). A Drosophila resource of transgenic RNAi  
838 lines for neurogenetics. *Genetics* 182, 1089–1100.  
839 <https://doi.org/10.1534/GENETICS.109.103630>.

840 26. Pan, Y., Li, W., Deng, Z., Sun, Y., Ma, X., Liang, R., Guo, X., Sun, Y., Li, W., Jiao, R., et  
841 al. (2022). Myc suppresses male-male courtship in Drosophila. *EMBO J* 41.  
842 <https://doi.org/10.15252/EMBJ.2021109905>.

843 27. Riemensperger, T., Issa, A.R., Pech, U., Coulom, H., Nguyẽn, M.V., Cassar, M., Jacquet,  
844 M., Fiala, A., and Birman, S. (2013). A single dopamine pathway underlies progressive  
845 locomotor deficits in a Drosophila model of Parkinson disease. *Cell Rep* 5, 952–960.  
846 <https://doi.org/10.1016/J.CELREP.2013.10.032>.

847 28. Brand, H., and Perrimon, N. (1993). Targeted gene expression as a means of altering cell  
848 fates and generating dominant phenotypes.

849 29. Bayersdorfer, F., Voigt, A., Schneuwly, S., and Botella, J.A. (2010). Dopamine-dependent  
850 neurodegeneration in Drosophila models of familial and sporadic Parkinson's disease.  
851 *Neurobiol Dis* 40, 113–119. <https://doi.org/10.1016/J.NBD.2010.02.012>.

852 30. Hovemann, B.T., Ryseck, R.P., Walldorf, U., Störtkuhl, K.F., Dietzel, I.D., and Dessen, E.  
853 (1998). The Drosophila ebony gene is closely related to microbial peptide synthetases  
854 and shows specific cuticle and nervous system expression. *Gene* 221, 1–9.  
855 [https://doi.org/10.1016/S0378-1119\(98\)00440-5](https://doi.org/10.1016/S0378-1119(98)00440-5).

856 31. Richardt, A., Rybak, J., Störkkuhl, K.F., Meinertzhangen, I.A., and Hovemann, B.T. (2002).  
857       Ebony protein in the *Drosophila* nervous system: optic neuropile expression in glial cells.  
858       *J Comp Neurol* **452**, 93–102. <https://doi.org/10.1002/CNE.10360>.

859 32. Yamamoto-Hino, M., Yoshida, H., Ichimiya, T., Sakamura, S., Maeda, M., Kimura, Y.,  
860       Sasaki, N., Aoki-Kinoshita, K.F., Kinoshita-Toyoda, A., Toyoda, H., et al. (2015).  
861       Phenotype-based clustering of glycosylation-related genes by RNAi-mediated gene  
862       silencing. *Genes to Cells* **20**, 521–542. <https://doi.org/10.1111/gtc.12246>.

863 33. Riemensperger, T., Isabel, G., Coulom, H., Neuser, K., Seugnet, L., Kume, K., Iché-  
864       Torres, M., Cassar, M., Strauss, R., Preat, T., et al. (2011). Behavioral consequences of  
865       dopamine deficiency in the *Drosophila* central nervous system. *Proc Natl Acad Sci U S A*  
866       **108**, 834–839. <https://doi.org/10.1073/pnas.1010930108>.

867 34. Chiu, J.C., Low, K.H., Pike, D.H., Yildirim, E., and Edery, I. (2010). Assaying locomotor  
868       activity to study circadian rhythms and sleep parameters in *Drosophila*. *Journal of*  
869       *Visualized Experiments*. <https://doi.org/10.3791/2157>.

870 35. Dietzl, G., Chen, D., Schnorrer, F., Su, K.C., Barinova, Y., Fellner, M., Gasser, B.,  
871       Kinsey, K., Oppel, S., Scheiblauer, S., et al. (2007). A genome-wide transgenic RNAi  
872       library for conditional gene inactivation in *Drosophila*. *Nature* **448**, 151–156.  
873       <https://doi.org/10.1038/NATURE05954>.

874 36. Ni, J.Q., Zhou, R., Czech, B., Liu, L.P., Holderbaum, L., Yang-Zhou, D., Shim, H.S., Tao,  
875       R., Handler, D., Karpowicz, P., et al. (2011). A genome-scale shRNA resource for  
876       transgenic RNAi in *Drosophila*. *Nat Methods* **8**, 405–407.  
877       <https://doi.org/10.1038/NMETH.1592>.

878 37. Vissers, J.H.A., Manning, S.A., Kulkarni, A., and Harvey, K.F. (2016). A *Drosophila* RNAi  
879       library modulates Hippo pathway-dependent tissue growth. *Nature Communications* **2016**  
880       7:1 7, 1–6. <https://doi.org/10.1038/ncomms10368>.

881 38. Shafer, O.T., and Keene, A.C. (2021). The Regulation of Drosophila Sleep. Preprint at  
882 Cell Press, <https://doi.org/10.1016/j.cub.2020.10.082>  
883 <https://doi.org/10.1016/j.cub.2020.10.082>.

884 39. Diao, F., Ironfield, H., Luan, H., Diao, F., Shropshire, W.C., Ewer, J., Marr, E., Potter,  
885 C.J., Landgraf, M., and White, B.H. (2015). Plug-and-play genetic access to drosophila  
886 cell types using exchangeable exon cassettes. *Cell Rep* 10, 1410–1421.  
887 <https://doi.org/10.1016/j.celrep.2015.01.059>.

888 40. Lee, P.T., Zirin, J., Kanca, O., Lin, W.W., Schulze, K.L., Li-Kroeger, D., Tao, R.,  
889 Devereaux, C., Hu, Y., Chung, V., et al. (2018). A gene-specific T2A-GAL4 library for  
890 Drosophila. *Elife* 7. <https://doi.org/10.7554/ELIFE.35574>.

891 41. Kanca, O., Zirin, J., Garcia-Marques, J., Knight, S.M., Yang-Zhou, D., Amador, G.,  
892 Chung, H., Zuo, Z., Ma, L., He, Y., et al. (2019). An efficient CRISPR-based strategy to  
893 insert small and large fragments of DNA using short homology arms. *Elife* 8, e51539.  
894 <https://doi.org/10.7554/elife.51539>.

895 42. Janssens, J., Aibar, S., Taskiran, I.I., Ismail, J.N., Gomez, A.E., Aughey, G., Spanier, K.I.,  
896 Rop, F.V. De, González-Blas, C.B., Dionne, M., et al. (2022). Decoding gene regulation in  
897 the fly brain. *Nature* 601, 630–636. <https://doi.org/10.1038/S41586-021-04262-Z>.

898 43. Li, H., Janssens, J., de Waegeneer, M., Kolluru, S.S., Davie, K., Gardeux, V., Saelens,  
899 W., David, F.P.A., Brbić, M., Spanier, K., et al. (2022). Fly Cell Atlas: A single-nucleus  
900 transcriptomic atlas of the adult fruit fly. *Science* (1979) 375.  
901 <https://doi.org/10.1126/science.abk2432>.

902 44. Morin, X., Daneman, R., Zavortink, M., and Chia, W. A protein trap strategy to detect  
903 GFP-tagged proteins expressed from their endogenous loci in Drosophila.

904 45. Buszczak, M., Paterno, S., Lighthouse, D., Bachman, J., Planck, J., Owen, S., Skora,  
905 A.D., Nystul, T.G., Ohlstein, B., Allen, A., et al. (2007). The carnegie protein trap library: A

versatile tool for *Drosophila* developmental studies. *Genetics* 175, 1505–1531.  
<https://doi.org/10.1534/genetics.106.065961>.

46. Mao, Z., and Davis, R.L. (2009). Eight different types of dopaminergic neurons innervate the *Drosophila* mushroom body neuropil: Anatomical and physiological heterogeneity. *Front Neural Circuits* 3, 5. <https://doi.org/10.3389/NEURO.04.005.2009/BIBTEX>.

47. Voet, M. Van Der, Harich, B., Franke, B., and Schenck, A. (2016). ADHD-associated dopamine transporter, latrophilin and neurofibromin share a dopamine-related locomotor signature in *Drosophila*. *Mol Psychiatry* 21, 565–573. <https://doi.org/10.1038/mp.2015.55>.

48. Kume, K., Kume, S., Park, S.K., Hirsh, J., and Jackson, F.R. (2005). Dopamine is a regulator of arousal in the fruit fly. *Journal of Neuroscience* 25, 7377–7384. <https://doi.org/10.1523/JNEUROSCI.2048-05.2005>.

49. Nall, A.H., Shakhmantir, I., Cichewicz, K., Birman, S., Hirsh, J., and Sehgal, A. (2016). Caffeine promotes wakefulness via dopamine signaling in *Drosophila*. *Sci Rep* 6. <https://doi.org/10.1038/srep20938>.

50. Ni, J.Q., Markstein, M., Binari, R., Pfeiffer, B., Liu, L.P., Villalta, C., Booker, M., Perkins, L., and Perrimon, N. (2007). Vector and parameters for targeted transgenic RNA interference in *Drosophila melanogaster*. *Nature Methods* 2008 5:1 5, 49–51. <https://doi.org/10.1038/nmeth1146>.

51. McGary, K.L., Park, T.J., Woods, J.O., Cha, H.J., Wallingford, J.B., and Marcotte, E.M. (2010). Systematic discovery of nonobvious human disease models through orthologous phenotypes. *Proc Natl Acad Sci U S A* 107, 6544–6549. <https://doi.org/10.1073/pnas.0910200107>.

52. Nakashima, A., Ohnuma, S., Kodani, Y., Kaneko, Y.S., Nagasaki, H., Nagatsu, T., and Ota, A. (2016). Inhibition of deubiquitinating activity of USP14 decreases tyrosine hydroxylase phosphorylated at Ser19 in PC12D cells. *Biochem Biophys Res Commun* 472, 598–602. <https://doi.org/10.1016/J.BBRC.2016.03.022>.

932 53. Kawahata, I., Ohtaku, S., Tomioka, Y., Ichinose, H., and Yamakuni, T. (2015). Dopamine  
933 or biopterin deficiency potentiates phosphorylation at (40)Ser and ubiquitination of  
934 tyrosine hydroxylase to be degraded by the ubiquitin proteasome system. *Biochem  
935 Biophys Res Commun* 465, 53–58. <https://doi.org/10.1016/J.BBRC.2015.07.125>.

936 54. Birman, S., Morgan, B., Anzivino, M., and Hirsh, J. (1994). A novel and major isoform of  
937 tyrosine hydroxylase in *Drosophila* is generated by alternative RNA processing. *Journal  
938 of Biological Chemistry* 269, 26559–26567. [https://doi.org/10.1016/S0021-  
939 9258\(18\)47231-6](https://doi.org/10.1016/S0021-9258(18)47231-6).

940 55. Vié, A., Cigna, M., Toci, R., and Birman, S. (1999). Differential regulation of *Drosophila*  
941 tyrosine hydroxylase isoforms by dopamine binding and cAMP-dependent  
942 phosphorylation. *J Biol Chem* 274, 16788–16795.  
943 <https://doi.org/10.1074/JBC.274.24.16788>.

944 56. Gervasi, N.M., Scott, S.S., Aschrafi, A., Gale, J., Vohra, S.N., Macgibeny, M.A., Kar,  
945 A.N., Gioio, A.E., and Kaplan, B.B. (2016). The local expression and trafficking of tyrosine  
946 hydroxylase mRNA in the axons of sympathetic neurons. *RNA* 22, 883–895.  
947 <https://doi.org/10.1261/RNA.053272.115>.

948 57. Freeman, A., Pranski, E., Miller, R.D., Radmard, S., Bernhard, D., Jinnah, H.A., Betarbet,  
949 R., Rye, D.B., and Sanyal, S. (2012). Sleep fragmentation and motor restlessness in a  
950 *Drosophila* model of Restless Legs Syndrome. *Current Biology* 22, 1142.  
951 <https://doi.org/10.1016/J.CUB.2012.04.027>.

952 58. Chaudhuri, A., Bowling, K., Funderburk, C., Lawal, H., Inamdar, A., Wang, Z., and  
953 O'Donnell, J.M. (2007). Interaction of Genetic and Environmental Factors in a *Drosophila*  
954 Parkinsonism Model. *The Journal of Neuroscience* 27, 2457.  
955 <https://doi.org/10.1523/JNEUROSCI.4239-06.2007>.

956 59. Wang, Z., Ferdousy, F., Lawal, H., Huang, Z., Daigle, J.G., Izevbaye, I., Doherty, O.,  
957 Thomas, J., Stathakis, D.G., and O'Donnell, J.M. (2011). Catecholamines up integrates

958 dopamine synthesis and synaptic trafficking. *J Neurochem* **119**, 1294–1305.

959 <https://doi.org/10.1111/J.1471-4159.2011.07517.X>.

960 60. Zhang, Y.Q., Friedman, D.B., Wang, Z., Woodruff, E., Pan, L., O'Donnell, J., and Broadie,  
961 K. (2005). Protein expression profiling of the *Drosophila* fragile X mutant brain reveals up-  
962 regulation of monoamine synthesis. *Molecular and Cellular Proteomics* **4**, 278–290.  
963 <https://doi.org/10.1074/mcp.M400174-MCP200>.

964 61. Wicker-Thomas, C., and Hamann, M. (2008). Interaction of dopamine, female  
965 pheromones, locomotion and sex behavior in *Drosophila melanogaster*. *J Insect Physiol*  
966 **54**, 1423–1431. <https://doi.org/10.1016/j.jinsphys.2008.08.005>.

967 62. Takahashi, A. (2013). Pigmentation and behavior: potential association through  
968 pleiotropic genes in *Drosophila*.

969 63. Letizia, A., Bario, R., and Campuzano, S. (2007). Antagonistic and cooperative actions of  
970 the EGFR and Dpp pathways on the iroquois genes regulate *Drosophila* mesothorax  
971 specification and patterning. *Development* **134**, 1337–1346.  
972 <https://doi.org/10.1242/DEV.02823>.

973 64. Lu, J., Wang, Y., Wang, X., Wang, D., Pflugfelder, G.O., and Shen, J. (2022). The Tbx6  
974 Transcription Factor Dorsocross Mediates Dpp Signaling to Regulate *Drosophila* Thorax  
975 Closure. *Int J Mol Sci* **23**. <https://doi.org/10.3390/IJMS23094543>.

976 65. Zeitlinger, J., and Bohmann, D. (1999). Thorax closure in *Drosophila*: involvement of Fos  
977 and the JNK pathway. *Development* **126**, 3947–3956.  
978 <https://doi.org/10.1242/DEV.126.17.3947>.

979 66. Massey, J.H., Akiyama, N., Bien, T., Dreisewerd, K., Wittkopp, P.J., Yew, J.Y., and  
980 Takahashi, A. (2019). Pleiotropic Effects of ebony and tan on Pigmentation and Cuticular  
981 Hydrocarbon Composition in *Drosophila melanogaster*. *Front Physiol* **10**, 518.  
982 <https://doi.org/10.3389/FPHYS.2019.00518/BIBTEX>.

983 67. Zhang, S., Wang, R., and Wang, G. (2019). Impact of Dopamine Oxidation on  
984 Dopaminergic Neurodegeneration. *ACS Chem Neurosci* 10, 945–953.  
985 [https://doi.org/10.1021/ACSCHEMNEURO.8B00454/ASSET/IMAGES/MEDIUM/CN-2018-004545\\_0005.GIF](https://doi.org/10.1021/ACSCHEMNEURO.8B00454/ASSET/IMAGES/MEDIUM/CN-2018-004545_0005.GIF).

987 68. Davla, S., Artiushin, G., Li, Y., Chitsaz, D., Li, S., Sehgal, A., and van Meyel, D.J. (2020).  
988 AANAT1 functions in astrocytes to regulate sleep homeostasis. *Elife* 9, 1–48.  
989 <https://doi.org/10.7554/ELIFE.53994>.

990 69. DeAngelis, M.W., McGhie, E.W., Coolon, J.D., and Johnson, R.I. (2020). Mask, a  
991 component of the Hippo pathway, is required for Drosophila eye morphogenesis. *Dev Biol*  
992 464, 53–70. <https://doi.org/10.1016/j.ydbio.2020.05.002>.

993 70. Zhu, M., Zhang, S., Tian, X., and Wu, C. (2017). Mask mitigates MAPT- and FUS-  
994 induced degeneration by enhancing autophagy through lysosomal acidification.  
995 *Autophagy* 13, 1924–1938. <https://doi.org/10.1080/15548627.2017.1362524>.

996 71. Martinez, D., Zhu, M., Guidry, J.J., Majeste, N., Mao, H., Yanofsky, S.T., Tian, X., and  
997 Wu, C. (2021). Mask, the Drosophila ankyrin repeat and KH domain-containing protein,  
998 affects microtubule stability. *J Cell Sci* 134. <https://doi.org/10.1242/jcs.258512>.

999 72. Dubowy, C., and Sehgal, A. (2017). Circadian rhythms and sleep in Drosophila  
1000 melanogaster. *Genetics* 205, 1373–1397. <https://doi.org/10.1534/genetics.115.185157>.

1001 73. Cichewicz, K., Garren, E.J., Adiele, C., Aso, Y., Wang, Z., Wu, M., Birman, S., Rubin,  
1002 G.M., and Hirsh, J. (2017). A new brain dopamine-deficient Drosophila and its  
1003 pharmacological and genetic rescue. *Genes Brain Behav* 16, 394–403.  
1004 <https://doi.org/10.1111/GBB.12353>.

1005 74. Sidor, C.M., Brain, R., and Thompson, B.J. (2013). Mask proteins are cofactors of  
1006 Yorkie/YAP in the Hippo pathway. *Curr Biol* 23, 223–228.  
1007 <https://doi.org/10.1016/J.CUB.2012.11.061>.

1008 75. Sansores-Garcia, L., Atkins, M., Moya, I.M., Shahmoradgoli, M., Tao, C., Mills, G.B., and  
1009 Halder, G. (2013). Mask is required for the activity of the Hippo pathway effector Yki/YAP.  
1010 Curr Biol 23, 229–235. <https://doi.org/10.1016/J.CUB.2012.12.033>.

1011 76. Smith, R.K., Carroll, P.M., Allard, J.D., and Simon, M.A. (2002). MASK, a large ankyrin  
1012 repeat and KH domain-containing protein involved in Drosophila receptor tyrosine kinase  
1013 signaling. Development 129, 71–82. <https://doi.org/10.1242/DEV.129.1.71>.

1014 77. Zhu, M., Li, X., Tian, X., and Wu, C. (2015). Mask loss-of-function rescues mitochondrial  
1015 impairment and muscle degeneration of Drosophila pink1 and parkin mutants. Hum Mol  
1016 Genet 24, 3272–3285. <https://doi.org/10.1093/HMG/DDV081>.

1017 78. Lusk, J.B., Lam, V.Y.M., and Tolwinski, N.S. (2017). Epidermal Growth Factor Pathway  
1018 Signaling in Drosophila Embryogenesis: Tools for Understanding Cancer. Cancers  
1019 (Basel) 9. <https://doi.org/10.3390/CANCERS9020016>.

1020 79. Oh, H., and Irvine, K.D. (2010). Yorkie: the final destination of Hippo signaling. Trends  
1021 Cell Biol 20, 410. <https://doi.org/10.1016/J.TCB.2010.04.005>.

1022 80. Sen, A., Kalvakuri, S., Bodmer, R., and Cox, R.T. (2015). Clueless, a protein required for  
1023 mitochondrial function, interacts with the PINK1-Parkin complex in Drosophila. Dis Model  
1024 Mech 8, 577–589. <https://doi.org/10.1242/DMM.019208>.

1025 81. Wang, Z.H., Clark, C., and Geisbrecht, E.R. (2016). Drosophila clueless is involved in  
1026 Parkin-dependent mitophagy by promoting VCP-mediated Marf degradation. Hum Mol  
1027 Genet 25, 1946–1964. <https://doi.org/10.1093/HMG/DDW067>.

1028 82. Sen, A., and Cox, R.T. (2016). Clueless is a conserved ribonucleoprotein that binds the  
1029 ribosome at the mitochondrial outer membrane. Biol Open 5, 195–203.  
1030 <https://doi.org/10.1242/BIO.015313/-DC1>.

1031 83. Inagaki, H.K., De-Leon, S.B.-T., Wong, A.M., Jagadish, S., Ishimoto, H., Barnea, G.,  
1032 Kitamoto, T., Axel, R., and Anderson, D.J. (2012). Visualizing Neuromodulation In Vivo:

1033 TANGO-Mapping of Dopamine Signaling Reveals Appetite Control of Sugar Sensing.

1034 *Cell* 148, 583. <https://doi.org/10.1016/J.CELL.2011.12.022>.

1035 84. Sun, F., Zhou, J., Dai, B., Qian, T., Zeng, J., Li, X., Zhuo, Y., Zhang, Y., Wang, Y., Qian, C., et al. (2020). Next-generation GRAB sensors for monitoring dopaminergic activity in vivo. *Nat Methods* 17, 1156. <https://doi.org/10.1038/S41592-020-00981-9>.

1036 85. Kasture, A.S., Hummel, T., Sucic, S., and Freissmuth, M. (2018). Big Lessons from Tiny

1037 Flies: *Drosophila melanogaster* as a Model to Explore Dysfunction of Dopaminergic and

1038 Serotonergic Neurotransmitter Systems. *Int J Mol Sci* 19.

1039 <https://doi.org/10.3390/IJMS19061788>.

1040 86. Calleja, M., Herranz, H., Estella, C., Casal, J., Lawrence, P., Simpson, P., and Morata, G.

1041 (2000). Generation of medial and lateral dorsal body domains by the pannier gene of

1042 *Drosophila*. *Development* 127, 3971–3980. <https://doi.org/10.1242/DEV.127.18.3971>.

1043 87. Kennerdell, J.R., and Carthew, R.W. (2000). Heritable gene silencing in *Drosophila* using

1044 double-stranded RNA. *Nat Biotechnol* 18, 896–898. <https://doi.org/10.1038/78531>.

1045 88. Yamamoto, S., Charng, W.L., Rana, N.A., Kakuda, S., Jaiswal, M., Bayat, V., Xiong, B.,

1046 Zhang, K., Sandoval, H., David, G., et al. (2012). A mutation in EGF repeat-8 of notch

1047 discriminates between serrate/jagged and delta family ligands. *Science* (1979) 338,

1048 1229–1232. <https://doi.org/10.1126/science.1228745>.

1049 89. Marcogliese, P.C., Deal, S.L., Andrews, J., Harnish, J.M., Bhavana, V.H., Graves, H.K.,

1050 Jangam, S., Luo, X., Liu, N., Bei, D., et al. (2022). *Drosophila* functional screening of de

1051 novo variants in autism uncovers damaging variants and facilitates discovery of rare

1052 neurodevelopmental diseases. *Cell Rep* 38. <https://doi.org/10.1016/j.celrep.2022.110517>.

1053 90. Snel, B., Lehmann, G., Bork, P., and Huynen, M.A. (2000). STRING: a web-server to

1054 retrieve and display the repeatedly occurring neighbourhood of a gene.

1055 91. Davie, K., Janssens, J., Koldere, D., De Waegeneer, M., Pech, U., Kreft, Ł., Aibar, S.,

1056 Makhzami, S., Christiaens, V., Bravo González-Blas, C., et al. (2018). A Single-Cell

1059 Transcriptome Atlas of the Aging Drosophila Brain. *Cell* **174**, 982–998.e20.  
1060 <https://doi.org/10.1016/j.cell.2018.05.057>.

1061 92. Szklarczyk, D., Gable, A.L., Nastou, K.C., Lyon, D., Kirsch, R., Pyysalo, S., Doncheva,  
1062 N.T., Legeay, M., Fang, T., Bork, P., et al. (2021). The STRING database in 2021:  
1063 Customizable protein-protein networks, and functional characterization of user-uploaded  
1064 gene/measurement sets. *Nucleic Acids Res* **49**, D605–D612.  
1065 <https://doi.org/10.1093/nar/gkaa1074>.

1066 93. Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable,  
1067 A.L., Fang, T., Doncheva, N.T., Pyysalo, S., et al. (2023). The STRING database in 2023:  
1068 protein-protein association networks and functional enrichment analyses for any  
1069 sequenced genome of interest. *Nucleic Acids Res* **51**, D638–D646.  
1070 <https://doi.org/10.1093/nar/gkac1000>.

1071 94. Hu, Y., Flockhart, I., Vinayagam, A., Bergwitz, C., Berger, B., Perrimon, N., and Mohr,  
1072 S.E. (2011). An integrative approach to ortholog prediction for disease-focused and other  
1073 functional studies. *BMC Bioinformatics* **12**. <https://doi.org/10.1186/1471-2105-12-357>.

1074 95. Hamosh, A., Amberger, J.S., Bocchini, C., Scott, A.F., and Rasmussen, S.A. (2021).  
1075 Online Mendelian Inheritance in Man (OMIM®): Victor McKusick's magnum opus. *Am J  
1076 Med Genet A* **185**, 3259–3265. <https://doi.org/10.1002/ajmg.a.62407>.

1077 96. Abrahams, B.S., Arking, D.E., Campbell, D.B., Mefford, H.C., Morrow, E.M., Weiss, L.A.,  
1078 Menashe, I., Wadkins, T., Banerjee-Basu, S., and Packer, A. (2013). SFARI Gene 2.0: A  
1079 community-driven knowledgebase for the autism spectrum disorders (ASDs). *Mol Autism*  
1080 **4**. <https://doi.org/10.1186/2040-2392-4-36>.

1081 97. Cichewicz, K., Garren, E.J., Adiele, C., Aso, Y., Wang, Z., Wu, M., Birman, S., Rubin,  
1082 G.M., and Hirsh, J. (2017). A new brain dopamine-deficient Drosophila and its  
1083 pharmacological and genetic rescue. *Genes Brain Behav* **16**, 394–403.  
1084 <https://doi.org/10.1111/gbb.12353>.

1085 98. Hardie, S.L., and Hirsh, J. (2006). An improved method for the separation and detection  
1086 of biogenic amines in adult *Drosophila* brain extracts by high performance liquid  
1087 chromatography. *J Neurosci Methods* 153, 243–249.  
1088 <https://doi.org/10.1016/j.jneumeth.2005.11.001>.  
1089  
1090

# Pathway


Tyrosine



L-DOPA



Dopamine



Melanin


## Dopamine Screen

VDRC RNAi Cuticle Screen




458 hits



### Pigmentation Screen





### Behavior Effect




153 hits



35 priority hits



Dopamine  $\Delta$   
in head





Dopamine  $\Delta$  in brain







*clu*




**mask**

### Reduced mask levels








**A****B****C****D****E****F**




D



### Behavior “Outliers” ( $\pm 2SD$ )




**A**




**B**




**D**




**E**




**F**
















**G**



**H**





**A****B****B'****C****D****E**